<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition - Fisher, SA - 2019 | Cochrane Library</title> <meta content="Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition - Fisher, SA - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009768.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition - Fisher, SA - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009768.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009768.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition" name="citation_title"/> <meta content="Sheila A Fisher" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="sheila.fisher@ndcls.ox.ac.uk" name="citation_author_email"/> <meta content="Antony Cutler" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Carolyn Doree" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Susan J Brunskill" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Simon J Stanworth" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust and University of Oxford" name="citation_author_institution"/> <meta content="Cristina Navarrete" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="John Girdlestone" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009768.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009768.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009768.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009768.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; beta-Thalassemia [*therapy]; Chronic Disease; Graft vs Host Disease [epidemiology, *therapy]; Hematologic Neoplasms [mortality, *therapy]; Hematopoietic Stem Cell Transplantation [*adverse effects]; Incidence; *Mesenchymal Stem Cell Transplantation [mortality]; Randomized Controlled Trials as Topic; Recurrence" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009768.pub2&amp;doi=10.1002/14651858.CD009768.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009768\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009768\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","de","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009768.pub2",title:"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft\\u2010versus\\u2010host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition",firstPublishedDate:"Jan 30, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009768.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009768.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009768.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009768.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009768.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009768.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009768.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009768.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009768.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009768.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4246 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009768.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/appendices#CD009768-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/table_n/CD009768StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/table_n/CD009768StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sheila A Fisher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0003">Antony Cutler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0004">Carolyn Doree</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0005">Susan J Brunskill</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0006">Simon J Stanworth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0007">Cristina Navarrete</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information#CD009768-cr-0008">John Girdlestone</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information/en#CD009768-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009768.pub2">https://doi.org/10.1002/14651858.CD009768.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009768-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009768-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009768-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009768-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009768-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009768-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009768-abs-0001" lang="en"> <section id="CD009768-sec-0001"> <h3 class="title" id="CD009768-sec-0001">Background</h3> <p>Recipients of allogeneic haematopoietic stem cell transplants (HSCT) can develop acute or chronic, or both forms of graft‐versus‐host disease (a/cGvHD), whereby immune cells of the donor attack host tissues. Steroids are the primary treatment, but patients with severe, refractory disease have limited options and a poor prognosis. Mesenchymal stromal cells (MSCs) exhibit immunosuppressive properties and are being tested in clinical trials for their safety and efficacy in treating many immune‐mediated disorders. GvHD is one of the first areas in which MSCs were clinically applied, and it is important that the accumulating evidence is systematically reviewed to assess whether their use is favoured. </p> </section> <section id="CD009768-sec-0002"> <h3 class="title" id="CD009768-sec-0002">Objectives</h3> <p>To determine the evidence for the safety and efficacy of MSCs for treating immune‐mediated inflammation post‐transplantation of haematopoietic stem cells. </p> </section> <section id="CD009768-sec-0003"> <h3 class="title" id="CD009768-sec-0003">Search methods</h3> <p>We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library 2018, Issue 12), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (from 1990) and ongoing trial databases to 6 December 2018. No constraints were placed on language or publication status. </p> </section> <section id="CD009768-sec-0004"> <h3 class="title" id="CD009768-sec-0004">Selection criteria</h3> <p>We included RCTs of participants with a haematological condition who have undergone an HSCT as treatment for their condition and were randomised to MSCs (intervention arm) or no MSCs (comparator arm), to prevent or treat GvHD. We also included RCTs which compared different doses of MSCs or MSCs of different sources (e.g. bone marrow versus cord). We included MSCs co‐transplanted with haematopoietic stem cells as well as MSCs administered post‐transplantation of haematopoietic stem cells. </p> </section> <section id="CD009768-sec-0005"> <h3 class="title" id="CD009768-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> <p>We employed a random‐effects model for all analyses due to expected clinical heterogeneity arising from differences in participant characteristics and interventions. </p> </section> <section id="CD009768-sec-0006"> <h3 class="title" id="CD009768-sec-0006">Main results</h3> <p>We identified 12 completed RCTs (879 participants), and 13 ongoing trials (1532 enrolled participants planned). Of 12 completed trials, 10 compared MSCs versus no MSCs and two compared different doses of MSCs. One trial was in people with thalassaemia major, the remaining trials were for haematological malignancies. Seven trials administered MSCs to prevent GvHD, whereas five trials gave MSCs to treat GvHD. </p> <p>In the comparison of MSCs with no MSCs, cells were administered at a dose of between 10<sup>5</sup> and 10<sup>7</sup> cells/kg in either a single dose (six trials) or in multiple doses (four trials) over a period of three days to four months. The dose‐comparison trials compared 2 x 10<sup>6</sup> cells/kg with 8 x 10<sup>6</sup> cells/kg in two infusions, or 1 x 10<sup>6</sup> cells/kg with 3 x 10<sup>6</sup> cells/kg in a single infusion. </p> <p>The median duration of follow‐up in seven trials which administered MSCs prophylactically ranged from 10 to 60 months. In three trials of MSCs as treatment for aGvHD, participants were followed up for 90 or 100 days. In two trials of MSCs as treatment for cGvHD, the mean duration of follow‐up was 13.4 months (MSC group) and 23.6 months (control group) in one trial, and 56 weeks in the second trial. Five trials included adults only, six trials included adults and children, and one trial included children only. In eight trials which reported the gender distribution, the percentage of females ranged from 20% to 59% (median 35.8%). </p> <p>The overall quality of the included studies was low: randomisation methods were poorly reported and several of the included studies were subject to a high risk of performance bias and reporting bias. One trial which started in 2008 has not been published and the progress of this trial in unknown, leading to potential publication bias. The quality of evidence was therefore low or very low for all outcomes due to a high risk of bias as well as imprecision due to the low number of overall participants, and in some cases evidence based on a single study. We found that MSCs may make little or no difference in the risk of all‐cause mortality in either prophylactic trials (HR 0.85, 95% CI 0.50 to 1.42; participants = 301; studies = 5; I<sup>2</sup> = 34% ; low‐quality evidence) or therapeutic trials (HR 1.12, 95% CI 0.80 to 1.56; participants = 244; studies = 1; very low‐quality evidence), and no difference in the risk of relapse of malignant disease (prophylactic trials: RR 1.08, 95% CI 0.73 to 1.59; participants = 323; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence) compared with no MSCs. MSCs were well‐tolerated, no infusion‐related toxicity or ectopic tissue formation was reported. No study reported health‐related quality of life. In prophylactic trials, MSCs may reduce the risk of chronic GvHD (RR 0.66, 95% CI 0.49 to 0.89; participants = 283; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). This means that only 310 (95% CI 230 to 418) in every 1000 patients in the MSC arm are expected to develop chronic GvHD compared to 469 in the control arm. However, MSCs may make little or no difference to the risk of aGvHD (RR 0.86, 95% CI 0.63 to 1.17; participants = 247; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). In GvHD therapeutic trials, we are very uncertain whether MSCs improve complete response of either aGvHD (RR 1.16, 95% CI 0.79 to 1.70, participants = 260, studies = 1; very low‐quality evidence) or cGvHD (RR 5.00, 95%CI 0.75 to 33.21, participants = 40, studies = 1; very low‐quality evidence). </p> <p>In two trials which compared different doses of MSCs, we found no evidence of any differences in outcomes. </p> </section> <section id="CD009768-sec-0007"> <h3 class="title" id="CD009768-sec-0007">Authors' conclusions</h3> <p>MSCs are an area of intense research activity, and an increasing number of trials have been undertaken or are planned. Despite a number of reports of positive outcomes from the use of MSCs for treating acute GvHD, the evidence to date from RCTs has not supported the conclusion that they are an effective therapy. There is low‐quality evidence that MSCs may reduce the risk of cGvHD. New trial evidence will be incorporated into future updates of this review, which may better establish a role for MSCs in the prevention or treatment of GvHD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009768-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009768-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009768-abs-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009768-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009768-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009768-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009768-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009768-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009768-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009768-abs-0004" lang="en"> <h3>Mesenchymal stromal cells to treat or prevent graft‐versus‐host disease in stem cell transplant recipients </h3> <p><b>Review question</b> </p> <p>In people who receive a stem cell transplant for a haematological condition, can an additional infusion of mesenchymal stromal cells (MSCs) prevent the development of graft‐versus‐host disease (GvHD)? In people who have already developed GvHD as a result of their stem cell transplant, can MSCs improve their clinical outcome? </p> <p><b>Background</b> </p> <p>Patients with leukaemia or other blood disorders may be treated with blood stem cells from another person, but the immune cells in the graft can attack their tissues in a serious complication referred to as graft‐versus‐host disease (GvHD). Steroids are the standard treatment for GvHD, but if they are unable stop the damage then treatment options are limited. In order to look for potential new treatments, a number of hospitals around the world have investigated the use of MSCs for inhibiting GvHD. MSCs are a type of cell that can develop into connective tissue (e.g. bone or cartilage), but they have also been found to have anti‐inflammatory properties. For clinical trials, MSCs have been isolated from different tissue sources (e.g. bone marrow, fat, or umbilical cords) and then grown in large numbers in the laboratory. The MSC preparations are then injected intravenously into the patient at the time they have their stem cell transplant or afterward, either to prevent GvHD (prophylaxis) or to treat ongoing disease. For patients being treated for GvHD, is treatment with MSCs safe and effective against complications of inflammation associated with GvHD? </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to 6 December 2018. We identified 12 studies and 13 ongoing trials. Ten studies compared MSCs with a control group, and two studies compared different doses of MSCs. Five trials included only adults, whereas six trials include both adults and children and one trial was exclusively performed in children. Of the 12 completed trials, one trial was in people with inherited blood disorders (thalassaemia major), and 11 trials were in people with blood cancers. In seven trials, MSCs were given to prevent GvHD, whereas in five trials, MSCs were given to people who had already developed GvHD. MSCs were derived from umbilical cord in two trials, bone marrow in seven trials and adipose tissue in one trial; in two trials the origin of MSCs was unknown. In the comparison of MSCs with no MSCs, cells were administered at a dose of between 10<sup>5</sup> and 10<sup>7</sup> cells/kg. Seven trials gave MSCs in a single dose, whereas five trials gave multiple doses of MSCs. Trial participants were followed up for between 10 and 60 months, or in those who had already developed GvHD, up to two years. Three trials were funded and carried out by a commercial manufacturer, using their cultured mesenchymal stromal cells known as Prochymal. All trials included both men and women. </p> <p><b>Key results</b> </p> <p>MSCs may have little or no difference in the risk of death or relapse of malignant disease, in either GvHD prevention or treatment trials, as the quality of evidence was low. MSCs were well‐tolerated, no infusion‐related toxicity or ectopic tissue formation was reported. No study reported health‐related quality‐of‐life. In trials where MSCs were administered to prevent GvHD, MSCs may reduce the risk of developing chronic GvHD, but may make little or no difference to the risk of developing acute GvHD. In GvHD treatment trials, we are very uncertain whether MSCs improve complete response of either acute or chronic GvHD as the quality of evidence is very low. We found no differences in outcomes between participants who received a higher dose of MSCs when compared with those who received a lower dose of MSCs. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence is low or very low for all outcome measures, due to the small number of trials and low number of study participants included in this review. One trial started in 2008, but its results are unknown as it is not yet published. It is therefore difficult to draw conclusions or provide recommendations on the use of MSCs, either to prevent or treat GvHD. More trials with large numbers of study participants are needed to improve the quality of evidence. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009768-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009768-sec-0112"></div> <h3 class="title" id="CD009768-sec-0113">Implications for practice</h3> <section id="CD009768-sec-0113"> <p>The main positive finding from this review is the support for prophylactic use of mesenchymal stromal cells (MSCs) to reduce rates of chronic graft‐versus‐host disease (cGvHD) although the quality of evidence is currently low. This debilitating complication of allogeneic transplantation has been increasing in frequency, associated with the increasing age of the patient population and preference for mobilised peripheral blood rather than bone marrow as a stem cell source (<a href="./references#CD009768-bbs2-0064" title="FlowersME , MartinPJ . How we treat chronic graft‐versus‐host disease. Blood2015;125(4):272‐8. ">Flowers 2015</a>). Treatment options are limited for steroid refractory cGvHD, and MSCs may represent a safe preventative therapy although further confirmatory trials are required before this can be implemented into clinical practice. We have found no conclusive evidence for the use of MSCs in reducing all‐cause mortality in people with acute or chronic GvHD. </p> </section> <h3 class="title" id="CD009768-sec-0114">Implications for research</h3> <section id="CD009768-sec-0114"> <p>Replication of the findings for cGvHD with further well‐powered randomised controlled trials (RCTs) is needed to provide robust support for recommending the use of MSC as a complement or alternative to current standards of prophylaxis. The reviewed studies differed in the timing, dosage, source and production protocols of MSC administered, and these are all parameters that will need to be assessed in order to determine effective treatment regimens. Whether MSCs are more efficacious in paediatric patients and for different organ involvements are other areas for future investigation. Given the lack of conclusive evidence to date, future trials must be directed at achieving sufficient power to support or not the use of MSCs for treatment and prevention of GvHD and the factors discussed above which may affect efficacy. Furthermore, trials should be prospectively registered with a full study protocol with comprehensive details of the study design, participants and interventions, and results should be reported in full. </p> <p>MSCs are an area of intense research activity, and an increasing number of trials have been undertaken or are planned. Despite a number of reports of positive outcomes from the use of MSCs for treating acute GvHD (aGvHD), the evidence to date from RCTs has not supported the conclusion that they are an effective therapy. Therefore, it is imperative that future trials are directed at determining the potential of MSCs to treat aGvHD. There is low‐quality evidence that prophylactic use of MSCs may reduce the risk of cGvHD. Nevertheless, given the current lack of effective treatment strategies for preventing or treating cGvHD, this finding is encouraging and prompts renewed efforts by researchers to demonstrate significant efficacy. New trial evidence will be incorporated into future updates of this review, which may better establish any role for MSCs in clinical applications for GvHD (e.g. treatment or prophylaxis, acute or chronic, paediatric or adult, organ involvement). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009768-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009768-sec-0029"></div> <div class="table" id="CD009768-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> MSCs<br/> <b>Comparison:</b> No MSCs (control or placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>control/placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MSCs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality (prophylactic trials)</b> </p> <p>(over duration of trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.85</b> <br/> (0.50 to 1.42)*** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>301<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>326 per 1000**</b><br/> (232 to 460) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality (therapeutic trials)</b> </p> <p>(over duration of trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 1.12</b> (0.80 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>244 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>420 per 1000**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>344 per 1000**</b> </p> <p>(248 to 479)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety of MSC infusion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>334</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MSCs were well‐tolerated, no infusion‐related toxicity or ectopic tissue formation was reported in any study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(no studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse of malignant disease (prophylactic trials)</b> </p> <p>(&gt;12‐month follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>99 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>107 per 1000</b> </p> <p>(35 to 185)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.08</b> </p> <p>(0.73 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>323</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of acute GvHD (prophylactic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.86</b> <br/> (0.63 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>247<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b><br/> (246 to 457) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of chronic GvHD (prophylactic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.66</b> <br/> (0.49 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>283<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>469 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b><br/> (230 to 418) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute GvHD complete response (therapeutic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b> <br/> (0.79 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>260<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/> (236 to 508) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic GvHD complete response (therapeutic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.00</b> <br/> (0.75 to 33.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/> (75 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>GvHD:</b> graft‐versus‐host disease; <b>HR</b> : hazard ratio; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 for high risk of bias due to inclusion of trials that do not report methods of random sequence generation or allocation, are unblinded, or are subject to selective reporting.<br/> <sup>2</sup> Downgraded by 1 for imprecision as the total population size is less than 400 participants. </p> <p><sup>3</sup> Downgraded by 2 for imprecision as the total population size is less than 400 participants and evidence is based on only one study. </p> <p>*The assumed risk is based on the observed rate in controls.</p> <p>**The hazard ratio for all‐cause mortality has been converted to a relative risk to estimate the corresponding risk in the MSC group. </p> <p>*** A hazard ratio less than 1 indicates advantage to MSCs, a value greater than 1 indicates advantage to no MSCs. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009768-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009768-sec-0030"></div> <section id="CD009768-sec-0031"> <h3 class="title" id="CD009768-sec-0031">Description of the condition</h3> <p>Graft‐versus‐host disease (GvHD) is a potentially life‐threatening complication of allogeneic haematopoietic stem cell transplantation (HSCT) used as a treatment for patients with haematological malignancies, severe aplastic anaemia and rare inherited genetic abnormalities. GvHD arises when donor immune cells that are contained within or differentiate from the stem cell transplant 'attack' host tissues, in effect rejecting the host as a foreign entity. Multiple organs are involved with the liver, skin and gastrointestinal tract being particularly affected. Acute GvHD (aGvHD) is a common complication and up to 80% of HSCT recipients can develop varying degrees of disease. Severity of disease is graded from I to IV depending on the extent of involvement of the three target organs. Between 50% and 80% of patients respond to standard first‐line therapies based on steroids. Patients who do not respond have a poor outlook and the five‐year survival of severe acute or steroid‐refractory GvHD patients is between 5% and 25% (<a href="./references#CD009768-bbs2-0078" title="MartinPJ , SchochG , FisherL , ByersV , AnasettiC , AppelbaumFR , et al. A retrospective analysis of therapy for acute graft‐versus‐host disease: initial treatment. Blood1990;76(8):1464‐72. ">Martin 1990</a>; <a href="./references#CD009768-bbs2-0086" title="VanLintMT , UderzoC , LocasciulliA , MajolinoI , ScimeR , LocatelliF , et al. Early treatment of acute graft‐versus‐host disease with high‐ or low‐dose 6‐methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood1998;92(7):2288‐93. ">Van Lint 1998</a>). Current second‐line therapies used after failure of steroid treatment are numerous, but have shown little efficacy in reducing death. Recent studies have started to suggest that mesenchymal stromal cells (MSCs) may be effective as a second‐line therapy, with a reported response in up to 50% of patients (<a href="./references#CD009768-bbs2-0075" title="LeBlancK , FrassoniF ,  BallL ,  LocatelliF ,  RoelofsH ,  LewisI ,  etal . Mesenchymal stem cells for treatment of steroid‐resistant, severe, acute graft‐versus‐host disease: a phase II study. Lancet2008;371(9624):1579‐86. ">Le Blanc 2008</a>). </p> <p>Chronic GvHD (cGvHD) is immunologically distinct from aGvHD and generally manifests after 100 days post‐transplant (<a href="./references#CD009768-bbs2-0064" title="FlowersME , MartinPJ . How we treat chronic graft‐versus‐host disease. Blood2015;125(4):272‐8. ">Flowers 2015</a>; <a href="./references#CD009768-bbs2-0084" title="SociéG , RitzJ . Current issues in chronic graft‐versus‐host disease. Blood2014;124(3):374‐84. ">Socié 2014</a>). The recorded incidence of cGvHD has risen over the last few decades, a trend ascribed to the transplantation of older patients and the increased use of peripheral blood stem cells as compared to bone marrow. Acute GvHD is a prominent risk factor for cGvHD, and therefore the prevention or amelioration of early immune complications is desirable. </p> <p>In this review we wish to identify and appraise the complete current literature reporting on the outcome of randomised, controlled trials to determine whether MSC infusion is safe, can reduce inflammation induced by immune‐mediated destruction of host tissues, and provide clinical benefit to patients where GvHD is a potential complication. </p> </section> <section id="CD009768-sec-0032"> <h3 class="title" id="CD009768-sec-0032">Description of the intervention</h3> <p>MSCs are increasingly being applied as an experimental cellular therapy for many different clinical indications. Identified originally in cultures of bone marrow, they may be derived from a number of tissues and are identified by a panel of cell surface markers, and their ability to differentiate into connective tissue elements: osteoblasts, chondrocytes, and adipocytes (<a href="./references#CD009768-bbs2-0061" title="DominiciM , LeBlancK , MuellerI , Slaper‐CortenbachI , MariniF , KrauseD , et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy2006;8(4):315‐7. ">Dominici 2006</a>). Originally envisioned as a treatment for damaged bone and cartilage, the finding that MSCs possess immunosuppressive properties has focused their use on treating immune‐mediated inflammation associated with transplantation of haematopoietic stem cells (<a href="./references#CD009768-bbs2-0082" title="RingdenO , LeBlancK . Mesenchymal stem cells for treatment of acute and chronic graft‐versus‐host disease, tissue toxicity and hemorrhages. Best Practice and Research: Clinical Haematology2011;24(1):65‐72. ">Ringden 2011</a>) or solid organs (<a href="./references#CD009768-bbs2-0062" title="EnglishK , FrenchA , WoodKJ . Mesenchymal stromal cells: facilitators of successful transplantation?. Cell Stem Cell2010;7(4):431‐42. ">English 2010</a>), and autoimmune diseases (<a href="./references#CD009768-bbs2-0059" title="DazziF , KramperaM . Mesenchymal stem cells and autoimmune diseases. Best Practice and Research: Clinical Haematology2011;24(1):49‐57. ">Dazzi 2011</a>). At present, the prophylaxis and treatment of GvHD are amongst the applications of MSC for which clinical trials are the most advanced. </p> <p>Bone marrow and adipose tissue are the main sources that have can be exploited for the generation of autologous MSCs. However, not all patients are able to donate sufficient material to generate the required cell numbers within the time needed for treatment. Therefore, allogeneic MSCs have been used in many trials, without human leukocyte antigen (HLA) matching and with no apparent adverse outcomes as compared to autologous, and low rates of donor‐specific anti‐HLA antibody development (<a href="./references#CD009768-bbs2-0066" title="HareJM , FishmanJE , GerstenblithG , DiFede VelazquezDL , ZambranoJP , SuncionVY , et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA2012;308(22):2369‐79. ">Hare 2012</a>; <a href="./references#CD009768-bbs2-0067" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El‐KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON‐DCM trial. Journal of the American Journal of Cardiology2017;69(5):526‐37. ">Hare 2017</a>). Increasingly, umbilical cord is being used as an allogeneic source of clinical‐grade MSCs due to the ease of acquisition and expansion (<a href="./references#CD009768-bbs2-0056" title="CapelliC , PedriniO , ValgardsdottirR , DaRoitF , GolayJ , IntronaM . Clinical grade expansion of MSCs. Immunology Letters2015;168(2):222‐7. ">Capelli 2015</a>). While fetal calf serum has traditionally been used in MSC culture medium, platelet lysate is now accepted as a suitable source of non‐xenogeneic growth factors (<a href="./references#CD009768-bbs2-0056" title="CapelliC , PedriniO , ValgardsdottirR , DaRoitF , GolayJ , IntronaM . Clinical grade expansion of MSCs. Immunology Letters2015;168(2):222‐7. ">Capelli 2015</a>). </p> <p>MSCs generally are infused intravenously into patients in single or multiple doses. Relatively low numbers of cells are infused with doses based on weight (ranging from 0.4 x 10<sup>6</sup> to 9 x 10<sup>6</sup> cells /kg) in the case of therapy for GvHD. The timing of intervention varies between diseases and disease states. In general, MSC therapy appears to be safe with few reported adverse reactions (<a href="./references#CD009768-bbs2-0074" title="LaluMM , McIntyreL , PuglieseC , FergussonD , WinstonBW , MarshallJC , et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta‐analysis of clinical trials. PLOs One2012;7(10):e47559. ">Lalu 2012</a>). However, one study reported an increase in relapse rates upon treatment with MSCs (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>). In most cases MSCs are infused in addition to standard care and are compared with control groups that are treated with placebo and standard care or standard care alone. </p> </section> <section id="CD009768-sec-0033"> <h3 class="title" id="CD009768-sec-0033">How the intervention might work</h3> <p>MSCs produce growth factors to aid tissue regeneration (<a href="./references#CD009768-bbs2-0057" title="CaplanAI , DennisJE . Mesenchymal stem cells as trophic mediators. Journal of Cell Biochemistry2006;98(5):1076‐84. ">Caplan 2006</a>) and have potent anti‐inflammatory potential with the ability to suppress the activation and effector function of cells of the immune system. They appear to employ multiple mechanisms to suppress inflammation, utilising secreted factors (prostaglandins), enzymes (indoleamine 2,3‐deoxygenase) and other agents to inhibit a number of immune cell types (<a href="./references#CD009768-bbs2-0063" title="FibbeWE , NautaAJ , RoelofsH . Modulation of immune responses by mesenchymal stem cells. Annals of the New York Academy of Sciences2007;1106:272‐8. ">Fibbe 2007</a>). They reduce the proliferative capacity of naive and memory T‐cells, B cells and effector function of γδT‐cells, natural killer cells and neutrophils. They also modulate the function of cells that are able to induce potent immune responses, such as monocytes and dendritic cells. </p> <p>In order for relatively low cell numbers to exert meaningful effects on strong immune activities such as GvHD, it has been thought that infused MSC accumulate at sites of inflammation and tissue damage, or draining lymph nodes (<a href="./references#CD009768-bbs2-0077" title="LeibacherJ , HenschlerR . Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Research and Therapy2016;7:7. ">Leibacher 2016</a>). The majority are found in the lung immediately after infusion, with some appearing later in the liver and spleen (<a href="./references#CD009768-bbs2-0065" title="GholamrezanezhadA , MirpourS , BagheriM , MohamadnejadM , AlimoghaddamK , AbdolahzadehL , et al. In vivo tracking of 111In‐oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nuclear Medicine and Biology2011;38(7):961‐7. ">Gholamrezanezhad 2011</a>). There is also an argument that any action by MSC is mediated by their release of exosomes while they are trapped in the lungs, and there is increasing interest in using such microvesicles rather than whole cells as the therapeutic treatment (<a href="./references#CD009768-bbs2-0080" title="RaniS , RyanAE , GriffinMD , RitterT . Mesenchymal stem cell‐derived extracellular vesicles: Toward cell‐free therapeutic applications. Molecular Therapy2015;23(5):812‐23. ">Rani 2015</a>). </p> </section> <section id="CD009768-sec-0034"> <h3 class="title" id="CD009768-sec-0034">Why it is important to do this review</h3> <p>There is increasing interest in the use of MSCs in the clinic and numerous small non‐randomised observational trials have already been completed. At present, the indications in which MSCs are used in most advanced clinical trials as a cellular therapy are the treatment of GvHD and Crohn’s disease. There is a now a need to identify and appraise the randomised controlled trial (RCT) evidence robustly for effectiveness and safety. </p> <p>The review will inform the wider clinical community as to the efficacy and safety of MSCs in their use as an anti‐inflammatory cellular therapy, and highlight the areas where further evidence is required. Furthermore, it will inform health organisations as to the cost‐effectiveness of banking MSCs to provide an 'off the shelf' service for treatment of GvHD and other indications. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009768-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009768-sec-0035"></div> <p>To determine the evidence for the safety and efficacy of mesenchymal stromal cells (MSCs) for treating or preventing graft‐versus‐host disease (GvHD) post‐transplantation of haematopoietic stem cells in patients with a haematological condition. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009768-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009768-sec-0036"></div> <section id="CD009768-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009768-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD009768-sec-0039"> <h4 class="title">Types of participants</h4> <p>All patients with a haematological condition who receive a haematopoietic stem cell transplant (HSCT) as treatment for their condition. </p> </section> <section id="CD009768-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Primary intervention: use of mesenchymal stromal cells (MSCs) as treatment or prophylaxis for acute or chronic graft‐versus‐host disease (aGvHD, cGvHD). </p> <p>We considered the following groups of trials.</p> <p> <ul id="CD009768-list-0001"> <li> <p>Use of MSCs versus placebo or no MSC treatment</p> </li> <li> <p>Use of MSCs of type (e.g. number of doses or passages) or source (e.g. autologous versus allogeneic, or bone marrow versus cord) A versus MSC of type or source B. </p> </li> </ul> </p> <p>We included MSCs co‐transplanted with haematopoietic stem cells as well as MSCs administered post‐transplantation of haematopoietic stem cells </p> </section> <section id="CD009768-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We considered outcomes common to all patient groups, as well as those relevant to either therapeutic or prophylactic trials. </p> <section id="CD009768-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009768-list-0002"> <li> <p>All‐cause mortality</p> </li> <li> <p>Safety of MSC infusion – acute toxicity, ectopic tissue formation or oncogenesis</p> </li> </ul> </p> </section> <section id="CD009768-sec-0043"> <h5 class="title">Secondary outcomes</h5> <section id="CD009768-sec-0044"> <h6 class="title">All studies</h6> <p> <ul id="CD009768-list-0003"> <li> <p>Health‐related quality of life using validated scale</p> </li> <li> <p>Relapse of malignant disease</p> </li> <li> <p>Infection rates</p> </li> <li> <p>Engraftment</p> </li> </ul> </p> </section> <section id="CD009768-sec-0045"> <h6 class="title">MSCs given for the prevention of GvHD</h6> <p> <ul id="CD009768-list-0004"> <li> <p>Incidence of aGvHD</p> </li> <li> <p>Incidence of cGvHD</p> </li> </ul> </p> </section> <section id="CD009768-sec-0046"> <h6 class="title">MSCs given as treatment for GvHD</h6> <p> <ul id="CD009768-list-0005"> <li> <p>Complete response and partial response to aGvHD</p> </li> <li> <p>Complete response and partial response to cGvHD</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD009768-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009768-sec-0048"> <h4 class="title">Electronic searches</h4> <p>The Systematic Review Initiative's (SRI) Information Specialist (CD) formulated the search strategies used in collaboration with the Cochrane Haematological Malignancies Group. We searched for randomised controlled trials (RCTs) in the following databases to 6 December 2018. </p> <p> <ul id="CD009768-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library, 2018, Issue 12) (www.cochranelibrary.com/) (<a href="./appendices#CD009768-sec-0118">Appendix 1</a>) </p> </li> <li> <p>MEDLINE (OvidSP, Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, 1946 to present) (<a href="./appendices#CD009768-sec-0119">Appendix 2</a>) </p> </li> <li> <p>Embase (OvidSP, 1974 to present) (<a href="./appendices#CD009768-sec-0120">Appendix 3</a>) </p> </li> <li> <p>CINAHL (EbscoHost, 1937 to present) (<a href="./appendices#CD009768-sec-0121">Appendix 4</a>) </p> </li> <li> <p>PubMed (e‐publications ahead of print only) (http://www.ncbi.nlm.nih.gov/pubmed) (<a href="./appendices#CD009768-sec-0122">Appendix 5</a>) </p> </li> <li> <p>LILACS (1980 to present) (http://lilacs.bvsalud.org/en/) (<a href="./appendices#CD009768-sec-0123">Appendix 6</a>) </p> </li> <li> <p>Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (Thomson Reuters, 1990 to present). (<a href="./appendices#CD009768-sec-0124">Appendix 7</a>). </p> </li> </ul> </p> <p>We searched for ongoing trials in the following clinical trial registers.</p> <p> <ul id="CD009768-list-0007"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">https://www.clinicaltrials.gov/</a>) (<a href="./appendices#CD009768-sec-0125">Appendix 8</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). (<a href="./appendices#CD009768-sec-0126">Appendix 9</a>) </p> </li> <li> <p>HKU Clinical Trials Registry (HKUCTR) (http://www.hkuctr.com/) (<a href="./appendices#CD009768-sec-0127">Appendix 10</a>). </p> </li> </ul> </p> <p>We combined searches in MEDLINE and Embase with adaptations of the recommended Cochrane RCT search filters as detailed in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009768-bbs2-0076" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, (editors). In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>) and the relevant Scottish Intercollegiate Guidelines Network (SIGN) systematic review filters (www.sign.ac.uk/methodology/filters.html). Searches in CINAHL were combined with the SIGN randomised controlled trial and systematic review filters. Searches were not limited by language, year of publication or publication type. Search strategies for all databases are presented in the appendices. </p> <p>Eligible studies identified from searches to 10 October 2017 were incorporated into this review as included studies. Potential studies identified from the final search update prior to publication of this review (6 December 2018) were included as awaiting assessment and are denoted as such in <a href="./references#CD009768-sec-0138" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD009768-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We checked references of all identified trials, relevant review articles and current treatment guidelines for further literature. These searches were limited to the ’first generation’ reference lists. </p> <p>We attempted to contact the lead authors of ongoing trials which did not have an expected completion date or for which the completion date had passed but no publications had been identified. We also contacted the lead authors of relevant studies, study groups and international experts working in this field to identify any unpublished material, or to gather information regarding ongoing studies. </p> </section> </section> <section id="CD009768-sec-0050"> <h3 class="title" id="CD009768-sec-0050">Data collection and analysis</h3> <section id="CD009768-sec-0051"> <h4 class="title">Selection of studies</h4> <p>We selected studies according to Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009768-bbs2-0069" title="HigginsJP , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). One review author, Carolyn Doree (CD), initially screened all search hits for relevance against the eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, two other review authors (JG and either AC or SF) independently screened all the remaining hits (titles and abstracts) for relevance against the full eligibility criteria. We retrieved full‐text papers for all those references for which a decision of eligibility could not be made from title and abstract alone. We resolved differences of opinion through discussion and consensus. Studies which did not meet our eligibility criteria are detailed in the <a href="./references#CD009768-sec-0137" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD009768-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JG and either AC or SF) independently extracted data onto standardised forms. Disagreements were resolved through discussion and consensus. The review authors were not blinded to the names of authors, institutions, journals or the outcomes of the trials. We extracted the following data for each trial. </p> <p> <ul id="CD009768-list-0008"> <li> <p>Trial details: study citation(s), objectives, study design, location, setting, methods of treatment allocation, randomisation and blinding, inclusion and exclusion criteria, defined primary and secondary outcomes, length of follow‐up, data stratification, stopping rules described, statistical analyses and funding. </p> </li> <li> <p>Characteristics of participants: age, gender, disease, disease class, number of randomised participants, number of analysed participants, exclusions or withdrawals, reasons for exclusions or withdrawals, protocol violations. </p> </li> <li> <p>Characteristics of HSCT: source of HSCT, conditioning regimen, GvHD prophylaxis.</p> </li> <li> <p>Interventions: source of intervention, dosage and timing of intervention, nature of comparator, additional interventions administered, any differences between interventions. </p> </li> <li> <p>Outcomes: all‐cause mortality, safety of MSC infusion (acute toxicity, ectopic tissue formation, oncogenesis), adverse events, time to survival, health‐related quality of life, relapse of malignant disease, infection rates, engraftment. In GvHD therapeutic trials: complete and partial response, alleviation of all organ involvement (GvHD). In GvHD prophylactic trials: incidence of aGvHD, incidence of cGvHD. </p> </li> </ul> </p> <p>We emailed the authors of two publications arising from one trial (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>) to request further information regarding possible patient overlap and sample size differences between the two publications, which the authors kindly provided. We also emailed the lead author of one study (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>) to request clarity over some apparent data discrepancies regarding adverse events contained in the published paper; the correct data were kindly provided. </p> <p>Following data extraction, we assessed the quality of each included study by using the 'Risk of bias' tool in the Review Manager 5 software (<a href="./references#CD009768-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). </p> </section> <section id="CD009768-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SF and JG) independently assessed all included studies for possible risk of bias as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009768-bbs2-0070" title="HigginsJP , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We assessed the design, conduct and analysis of the trial using a three‐point scale: low risk of bias, high risk of bias or unclear. To assess risk of bias, we included the following questions in the 'Risk of bias' table for each included study. </p> <p> <ul id="CD009768-list-0009"> <li> <p>Selection bias: was the allocation sequence adequately generated? Was allocation adequately concealed? </p> </li> <li> <p>Performance bias: where possible, were the study participants and personnel adequately blinded? </p> </li> <li> <p>Detection bias:was blinding of the outcome assessors effective in preventing systematic differences in the way in which the outcomes were determined? </p> </li> <li> <p>Attrition bias: were incomplete outcome data adequately addressed for each outcome?</p> </li> <li> <p>Reporting bias: are reports of the study free of selective outcome reporting?</p> </li> <li> <p>Other sources of bias: was the study apparently free of other problems that could put it at risk of bias? </p> </li> </ul> </p> </section> <section id="CD009768-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p>Where sufficient data were available, we performed quantitative assessments using Review Manager (<a href="./references#CD009768-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). </p> <p>For dichotomous outcomes we recorded the number of events and the total number of participants in each treatment arm. We present dichotomous outcomes as pooled risk ratios (RR) with 95% confidence intervals (CI). For survival data we used hazard ratios (HR) to express the intervention effect. </p> </section> <section id="CD009768-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>We did not identify any cluster‐randomised trials or cross‐over studies eligible for inclusion in this review. </p> </section> <section id="CD009768-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>We assumed missing data to be due to random effects. We recorded the number of patients lost to follow‐up and excluded/withdrawn from each trial. If survival data were missing, we estimated log hazard ratios and standard errors using the methods from Parmar and Tierney (<a href="./references#CD009768-bbs2-0079" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD009768-bbs2-0085" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>). In two studies, individual patient survival data were presented, but in one study (<a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), survival analysis was not performed and in the other study (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>), insufficient data were presented to use estimation methods. In these studies, survival models were fitted to reported data using Cox proportional hazards regression, implemented using the statistical R v2.14.1 to calculate hazard ratios. Our preferred analysis was by intention‐to‐treat (ITT), but where insufficient data were presented in the included studies, we performed per protocol analyses. </p> </section> <section id="CD009768-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity within selected studies according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 9 (<a href="./references#CD009768-bbs2-0060" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We assessed statistical heterogeneity of treatment effects between trials by using a Chi<sup>2</sup> test with a significance level at P value &lt; 0.1. We used the I<sup>2</sup> statistic to quantify the amount of possible heterogeneity (we considered an I<sup>2</sup> &gt; 30% to indicate moderate heterogeneity and an I<sup>2</sup> &gt; 75% to indicate considerable heterogeneity). We intended to explore potential causes of heterogeneity by sensitivity and subgroup analysis but this was prohibited by the low number of included studies. </p> <p>If sufficient data are identified in future updates of this review, we will assess clinical heterogeneity based on the data extracted about the characteristics (e.g. by examining differences in study quality, in the donation history and donor characteristics, and in the definition or measurement of outcomes of each study) of the included studies. </p> </section> <section id="CD009768-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>We believe that every effort has been made to identify unpublished studies. A formal assessment of publication bias using funnel plots was intended but was not possible due to the paucity of studies (It is acknowledged that asymmetry, of which publication bias is one cause, is difficult to detect with the small numbers of studies (i.e. fewer than 10) often encountered in systematic reviews). </p> </section> <section id="CD009768-sec-0059"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analysis where we considered that studies were sufficiently homogeneous in terms of clinical setting and study design. Meta‐analysis was performed using the Review Manager software (<a href="./references#CD009768-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). We used random‐effects models throughout due to expected clinical heterogeneity due to differences in participant characteristics, cell doses and follow‐up time points. </p> <p>As well as quantitative synthesis, our overall interpretation of the data also incorporates insights from a qualitative summary. We have based our conclusions on patterns of results identified across clearly tabulated results of included studies as well as summary measures. </p> <p>For disease relapse, we analysed data separately according to the duration of follow‐up: short term (≤ 12 months) and long term (&gt; 12 months). </p> <p>We have used the GRADE profiler to create a 'Summary of findings' table as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 11 (<a href="./references#CD009768-bbs2-0083" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). We focus on those outcomes which we consider to be most clinically relevant for this intervention, namely all‐cause mortality, safety of MSC infusion, incidence of acute and chronic GvHD (prophylactic trials), and complete response to acute and chronic GvHD (therapeutic trials). </p> </section> <section id="CD009768-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where sufficient trials were identified, we intended to perform subgroup analyses according to the following criteria: </p> <p> <ul id="CD009768-list-0010"> <li> <p>participant (children versus adults);</p> </li> <li> <p>intervention (by type of MSC, e.g. number of doses or source);</p> </li> <li> <p>underlying disease (malignant versus non‐malignant);</p> </li> <li> <p>MSC usage (prophylactic versus therapeutic) (mortality and response outcomes).</p> </li> </ul> </p> <p>However, subgroup analyses were largely prohibited by the paucity of included studies. We only identified sufficient trials to perform subgroup analysis comparing malignant versus non‐malignant disease (incidence of aGvHD) and prophylactic versus therapeutic trials (all‐cause mortality). We will perform further subgroup analyses in future updates of the review if sufficient studies are identified. </p> </section> <section id="CD009768-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to assess the robustness of our findings through sensitivity analyses, however this was not feasible due to the limited number of studies included in meta‐analyses. We will perform the following sensitivity analyses in future updates of the review if sufficient studies are identified: </p> <p> <ul id="CD009768-list-0011"> <li> <p>including only those trials at low risk of selection bias (trials assessed as low risk for random sequence generation and concealment of treatment allocation); </p> </li> <li> <p>including only those trials in which 25% participants or less were lost to follow‐up;</p> </li> <li> <p>including only those trials which are published as full‐text papers (i.e. excluding abstract‐only publications and unpublished trials). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009768-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009768-sec-0062"></div> <section id="CD009768-sec-0063"> <h3 class="title">Description of studies</h3> <p>See <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011305.pub2/full#CD011305-sec2-0032" target="_blank">Characteristics of included studies</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011305.pub2/full#CD011305-sec2-0033" target="_blank">Characteristics of excluded studies</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011305.pub2/full#CD011305-sec2-0034" target="_blank">Characteristics of studies awaiting classification</a> and <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011305.pub2/full#CD011305-sec2-0035" target="_blank">Characteristics of ongoing studies</a>. </p> <section id="CD009768-sec-0064"> <h4 class="title">Results of the search</h4> <p>See the PRISMA Flow Diagram (<a href="#CD009768-fig-0001">Figure 1</a>). From searches carried out to 6 December 2018, we identified a total of 4601 records, comprising 3848 published papers or conference abstracts, and 753 ongoing trial records. We also identified four additional references resulting from subsequent detailed screening as follows. One published trial (<a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>) was identified though checking of reference lists of a relevant published systematic review (this trial was included in the initial search results but excluded on the basis of the abstract). Additionally, two commercially sponsored studies were published in abstract form only (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). We attempted to contact both Osiris Therapeutics Inc. and Mesoblast Ltd (who have acquired Osiris' stem cell unit since these trials were performed) by email with a request for further information on these trials, but no response was forthcoming. However, we identified an Australian Public Assessment Report and associated document relating to a submission to register Remestemcel‐L (Prochymal) (subsequently withdrawn), which include detailed data relating to the trial described in <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>. Permission to obtain these data was obtained from the Therapeutic Goods Administration, Australian Government subject to copyright (see <a href="./appendices#CD009768-sec-0128">Appendix 11</a>). We also identified a press release relating to <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a> through searches of Google. From all available identified records, removal of 1313 duplicate references by the Information Specialist (CD) resulted in a total of 3292 records for screening. </p> <div class="figure" id="CD009768-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009768-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Two out of three review authors (AC, SF, JG) screened all records and excluded 3203 records on the basis of the abstract or title alone. The full texts of the remaining 89 records (53 references and 36 ongoing trial records) were assessed for inclusion against detailed eligibility criteria. Of these, 36 records describing 28 independent trials were excluded; details are listed in the <a href="./references#CD009768-sec-0137" title="">Characteristics of excluded studies</a> table. We also identified 14 ongoing trial records describing 13 independent trials which met the eligibility criteria for this review, but are yet to be completed or published (see <a href="./references#CD009768-sec-0139" title="">Characteristics of ongoing studies</a>). Two studies identified in the final search update appeared to meet eligibility criteria but were not fully evaluated; these studies were included as <a href="./references#CD009768-bbs1-0003" title="">Studies awaiting classification</a> and will be incorporated into future updates of this review. The remaining 37 records (28 references and nine ongoing trial records) described a total of 12 trials which are included in this review (one press release article described two trials (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). All included studies were published in English. </p> </section> <section id="CD009768-sec-0065"> <h4 class="title">Included studies</h4> <p>See <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011305.pub2/full#CD011305-sec2-0032" target="_blank">Characteristics of included studies</a> for full details of each study. </p> <section id="CD009768-sec-0066"> <h5 class="title">Trial design and setting</h5> <p>We identified a total of 12 eligible RCTs which included a total of 879 (range 14 to 260) randomised participants (two trials only reported the number of analysed participants which are included here (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>)). Two studies were phase three trials (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), five were phase two trials (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), one trial was a pilot study (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>), and in four trials the trial design phase was not reported. Ten trials compared MSCs with a control or placebo (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) and two trials (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>) were mesenchymal stromal cell (MSC) dose‐comparison trials with no control group. All were parallel two‐arm trials. Four trials were published in abstract form only (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) although in one trial, a submission to the Therapeutic Goods Administration, Australian Government to register Remestemcel‐L (Prochymal) (subsequently withdrawn) was identified and data were extracted from documents relating to this application (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). One further trial identified through searches of ongoing trial databases was unpublished; however a press release was identified and data were extracted from the information contained therein (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>). All other trials were published as full papers. </p> <p>In seven trials, MSCs were administered as a prophylactic intervention for graft‐versus‐host disease (GvHD) (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), and in five trials MSCs were administered as treatment for GvHD (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> <p>Five trials were performed in China (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) including one multicentre trial (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>). Three additional multicentre trials were performed in the USA (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), USA/Australia/Canada (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>) and USA/Australia/Canada/Europe (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). The remaining trials were performed in Spain (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>), Iran <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>), Russia (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>), and Belarus (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>). </p> <p>The median duration of follow‐up in seven trials that administered MSCs prophylactically ranged from 10 months to 60 months, with individual participant follow‐up ranging from one month (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>) to 70 months (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>). In three trials which administered MSCs as treatment for acute GvHD (aGvHD), participants were followed up for 90 days (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>) or 100 days (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). In two trials of MSCs as treatment for chronic GvHD (cGvHD), the mean duration of follow‐up was 13.4 months (MSC group) and 23.6 months (control group) (<a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015)</a>, or 56 weeks (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> </section> <section id="CD009768-sec-0067"> <h5 class="title">Study participants</h5> <p>See <a href="#CD009768-tbl-0002">Table 1</a> for a summary of study participants. In 11 trials, participants had a range of haematological malignancies including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoid leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome and non‐Hodgkins lymphoma. Of five trials which administered MSCs as therapy for GvHD, three included participants with aGvHD, either newly diagnosed (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>), requiring systemic steroid therapy (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), or refractory to steroid therapy (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), and in two trials participants had extensive cGvHD (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). The extent of disease differed across trials with severe disease (defined as Grade III/IV or C/D) occurring in over 70% of patients in one trial (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) compared with around 30% in another trial (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>) A third trial recruited patients with "newly diagnosed" GVHD with primarily involvement of the skin (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>). Multiple organ involvement was described in one trial (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). One trial described a cohort of participants with class III thalassaemia major (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>). </p> <div class="table" id="CD009768-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HSCT source</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conditioning regimen</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GvHD prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment arm</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number analysed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age distribution (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Female</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GvHD involvement</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HLA‐haploidentical transplants, haematological malignancies without ongoing or cGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ALL: TBI plus Ara‐C, CY and ATG.</p> <p>AML/MDS: CCNU, Ara‐C, BU, CY and ATG.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MMF, and short term MTX.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18 (15), 18‐40 (39), &gt; 40 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (43), ALL (14), MDS (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (48), CR2 (8), PR (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18 (13), 18‐40 (43), &gt; 40 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (42), ALL (16), MDS (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (39), CR2 (15), PR (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thalassaemia major</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB or BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CY or fludarabine based</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Class III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Class III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; cGvHD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (3), RIC (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (3 x 10<sup>6</sup> cells/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 45.5 (SD 7.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lymphomas (3), acute leukemias (2), myeloma (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cGvHD: moderate (3), severe (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (1 x 10<sup>6</sup> cells/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 51.1 (SD 10.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lymphomas (6), acute leukemias (2), myeloma (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cGvHD: moderate (4), severe (5)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; aGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (27), RIC (10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX, some additionally received MMF or prednisolone.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 34 (range 20‐63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (14), ALL (2), CML (3), CLL (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR (19), non‐CR (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 29 (range 19‐60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (10), ALL (4), CML (3), CLL (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR (15), non‐CR (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies in complete remission</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>G‐CSF mobilised BM and PB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BU, CA, CY, ATG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 30 (range 14‐46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (8), AML (13), CML (6), High risk (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (23), CR2 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 31.5 (range 12‐48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (16), AML (7), CML (5), High risk (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (24), CR2 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 13 (range 5‐24) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (8), AML (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 13 (range 5‐24) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (7), AML (4), MDS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB (16), BM (10), PB+BM (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TBI, CY (BU, CY in one patient)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 38 (range 17‐52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (8), CML (4), ALL (2), MDS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (9), CP (3), first relapse (1), CP2 (1), RAS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 37 (range 16‐61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (7), CML (4), ALL (2), NHL (1), MDS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (8), CR2 (1), CP (2), CP2 (2), RAS (1), non‐relapse (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; acute GvHD II‐IV requiring systemic steroid therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB (30), BM (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (15), RIC (8), non‐myeloablative(4), DLI (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CsA (6), tacrolimus (10), tacrolimus plus MMF or MTX (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (8 x 10<sup>6</sup> cells/kg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 49 (range 34‐67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (8), NHL (2), CLL (1), ALL (3), MM (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade II (10), grade III (4), grade IV (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (2 x 10<sup>6</sup> cells/kg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 53 (range 42‐67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (6), NHL (3), CLL (3), ALL (1), MMF (2), MM (0), Hodgkin's (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade II (11), grade III (3), grade IV (2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; newly diagnosed aGvHD grades B‐D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BM/PB/CB/DLI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MTP (or equivalent)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r [192 in total]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r [192 in total]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B‐D, mostly skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B‐D, mostly skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; steroid‐refractory aGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB (197), other (63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (177), other (83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Standard of care"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 42.3 (SD 17.2) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (49), other (124)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B (38), grade C (88), grade D (47).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 42.3 (SD 17.2) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (23), other (64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B (23), grade C (50), grade D (14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies (high risk leukaemia)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ALL: CY, etoposide, TBI<br/> AML: BU, CY </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTP, ATG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 9.8 (range 3.2‐12.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (3), AML (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd remission (3), MDS (2), Ph (2), monosomy 7 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: none (4), grade I (3), grade II (1).</p> <p>cGvHD: none (7), limited (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 8.5 (range 3.6‐13.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (5), AML (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd remission (6), 1st remission (2), MDS (2), Ph (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: none (4), grade I (5), grade II (2), grade III (1)</p> <p>cGvHD: none (7), limited (4), extensive (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies, extensive cGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>extensive cGvHD in skin and/or liver</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>extensive cGvHD in skin and/or liver</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>aGvHD:</b> acute graft‐versus‐host disease; <b>ALL:</b> acute lymphoblastic leukaemia; <b>AML:</b> acute myeloid leukaemia; <b>Ara‐C:</b> arabinosylcytosine; <b>ATG:</b> antithymocyte globulin; <b>BU:</b> busulphan; <b>CA:</b> cytosine arabinoside; <b>CB:</b> cord blood; <b>CCNU:</b> chlorethyl cyclohexyl nitrosourea; <b>cGvHD:</b> chronic graft‐versus‐host disease; <b>CLL:</b> chronic lymphoid leukaemia; <b>CML:</b> chronic myeloid leukaemia; <b>CP:</b> chronic phase; <b>CP2:</b> second chronic phase; <b>CR:</b> complete remission; <b>CR1:</b> complete first remission; <b>CR2:</b> complete second remission; <b>CSA:</b> cyclosporine A; <b>CY:</b> cyclophosphamide; <b>DLI:</b> donor lymphocyte infusion; <b>ITT:</b> intention‐to‐treat; <b>MAC:</b> myeloablative conditioning; <b>MDS:</b> myelodysplastic syndrome; <b>MF:</b> myelofibrosis; <b>MM:</b> multiple myeloma; <b>MMF:</b> mycophenolate mofetil; <b>MSC:</b> mesenchymal stromal cells; <b>MTP:</b> methylprednisolone; <b>MTX:</b> methotrexate; <b>N/A:</b> not applicable;<b>NHL:</b> non‐Hodgkins lymphoma; <b>PB:</b> peripheral blood; <b>Ph:</b> Philadelphia chromosome;<b>PR:</b> partial remission; <b>RAS</b> :refractory anaemia with ringed sideroblasts; <b>RIC:</b> reduced intensity conditioning;<b>TBI:</b> total body irradiation; </p> </div> </div> <p>The percentage of analysed participants who received the intervention ranged from 40% to 75% (median 50%). In the comparison of MSCs versus placebo, 364 participants (MSC group) and 268 participants (control group) were included in the analyses. One trial did not report the number of analysed participants in each intervention group (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>). In two trials which compared two different doses of MSCs, analyses included 31 participants (15 received 8 x 10<sup>6</sup> cells/kg; 16 received 2 x 10<sup>6</sup> cells/kg) (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), and 15 participants (six received 3 x 10<sup>6</sup> cells/kg; nine received 1 x 10<sup>6</sup> cells/kg) (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> <p>Five trials included only adults (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>), whereas six trials include both adults and children (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), although one trial focused on children and young adults (age range five to 24 years) (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>). One trial was exclusively performed in children (age range 3.2 to 13.1 years) (<a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). In eight trials which reported the distribution of males and females, the percentage of females in each study ranged from 20% to 59% (median 35.8%). </p> </section> <section id="CD009768-sec-0068"> <h5 class="title">Haematopoietic stem cell transplant (HSCT) characteristics</h5> <p>Seven trials reported the origin of haematopoietic stem cells. One trial administered cells obtained from cord blood (<a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), one trial administered cells taken from peripheral blood in all but one participant (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>); the remaining five trials obtained haematopoietic stem cells from a range of sources including bone marrow (mobilised with granulocyte colony‐stimulating factor (G‐CSF)) and peripheral blood. One trial included some patients who received a donor lymphocyte infusion (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>). </p> <p>Human leukocyte antigen<b>(</b>HLA) matching of donors was reported in eight trials. Two trials reported donors as "matched related" or "matched sibling" (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>); two further trials used a combination of matched related and matched unrelated donors (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), and one trial reported that donors were "HLA identical" (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>) Three trials reported the extent of matched or mismatched loci, (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>) (see <a href="./references#CD009768-sec-0136" title="">Characteristics of included studies</a> for further details). </p> <p>Nine trials reported on conditioning regimens, but four of these were only listed as myeloablative (MAC) or reduced intensity (RIC) (see <a href="#CD009768-tbl-0002">Table 1</a>). One trial reported the use of one conditioning regimen for all patients (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>), and one (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>) used a similar regimen (total body irradiation (TBI) 10‐12 Gy + cyclophosphamide) for all patients except one who received busulphan rather than TBI. Two trials reported using different regimens according to the disease (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). </p> <p>Two trials (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) did not report the regimen used for GvHD prophylaxis, and one listed “standard of care” (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) (see <a href="#CD009768-tbl-0002">Table 1</a>). One trial listed “methylprednisolone or equivalent” (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>), and eight used cyclosporine A together with one or more other immunosuppressants. </p> </section> <section id="CD009768-sec-0069"> <h5 class="title">Study Interventions</h5> <p>See <a href="#CD009768-tbl-0003">Table 2</a> for a summary of study interventions. </p> <div class="table" id="CD009768-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of interventions</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prophylactic or therapeutic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Source of MSCs</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Expansion protocol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose/Schedule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Timing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 x 10<sup>7</sup> cells/100mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (+4,+5,+6 and +7 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (100 mL normal saline at +4,+5,+6 and +7 months)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45‐1.8 x 10<sup>6</sup> cells/kg given in single intravenous infusion </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (4 hours prior to HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 x 10<sup>6</sup> cells/kg given as a single infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (within first week of cGvHD therapy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 x 10<sup>6</sup> cells/kg given as a single infusion </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelet lysate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜10<sup>6</sup> (range 0.9 ‐ 1.39) cells/kg as single infusion </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (Injected at the time of graft activation (leukocytes &gt;1 x 10<sup>9</sup>/L)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nutrient mixture of F12, 42% MCDB‐201 medium and 58% DMEM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐5 x 10<sup>5</sup> cells/kg </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (within 24 hours of HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 +/‐ 0.4 x 10<sup>6</sup> cells/kg </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (timing n/r)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 3.3 (range 0.3‐15.3) x 10<sup>5</sup> cells/kg given intravenously over 30 minutes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (4 hours prior to HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 x 10<sup>6</sup> cells/kg in two infusions given intravenously 3 days apart. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (first infusion within 24‐48 hours of aGvHD diagnosis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 x 10<sup>6</sup> cells/kg in two infusions given intravenously 3 days apart. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 x 10<sup>6</sup> cells/kg, total 6 infusions over 4 weeks: twice weekly for 2 weeks, then weekly for 2 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (first infusion within 72 hours of aGvHD diagnosis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (excipient, less cells, total 6 infusions over 4 weeks: twice weekly for 2 weeks, then weekly for 2 weeks) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 x 10<sup>6</sup> cells/kg, given as 8 infusions over 4 weeks, at least 3 days apart </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (timing n/r)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (iv infusions equivalent to the calculated volume of active treatment)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 7.19 (range 2.44 to 10.12) x 10<sup>6</sup> cells/kg infused over 30 minutes through central venous line </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (4 hours prior to HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4 x 10<sup>7</sup> cells/week, given weekly over four weeks, total 4.8‐16 x 10<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (timing n/r)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AT:</b> adipose tissue; <b>B:M</b> bone marrow; <b>DMEM:</b> Dulbecco's Modified Eagle's medium; <b>UC:</b> umbilical cord; n/r not reported; <b>PL:</b> platelet lysate<b>;BF:</b> fetal bovine serum </p> </div> </div> <p>MSCs were obtained from umbilical cord (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), from allogeneic bone marrow (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) or from adipose tissue (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). Two trials did not report the origin of MSCs (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). Six trials reported the MSC expansion protocol: five trials cultured MSCs using fetal bovine serum (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), one used platelet lysate (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>) and one used a nutrient mixture of F12, 42% MCDB‐201 medium and 58% Dulbecco's Modified Eagle's medium (DMEM). </p> <p>Co‐transplantation of haematopoietic stem cells and MSCs was reported in five trials. MSCs were administered four hours prior to stem cell transplantation (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), within 24 hours of stem cell transplantation (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>), or at the time of graft activation (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>). The timing of MSC administration was not reported in two trials (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>). MSCs were given post‐HSCT in five trials, at four, five, six and seven months after stem cell transplantation (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>) and as treatment for GvHD in four trials (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> <p>MSCs were administered at a median dose of approximately 10<sup>5</sup> cells/kg (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>), 10<sup>6</sup> cells/kg (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), or 10<sup>7</sup> cells/kg (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), as a single infusion (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>) or as multiple infusions, given as two infusions three days apart (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), weekly infusions over four weeks (<a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), six infusions over four weeks (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>), eight infusions over four weeks (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), or monthly over four months (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>). </p> <p>Three trials administered a placebo infusion at the equivalent dose and schedule to the MSC trial arm, whereas in seven trials, no placebo was administered. One dose‐comparison trial compared a high dose of MSCs (8 x 10<sup>6</sup> cells/kg) with a low dose of MSCs (2 x 10<sup>6</sup> cells/kg) (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>); the other compared a 3 x 106 cells/kg with a lower dose of 1 x 10<sup>6</sup> cells/kg (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> </section> <section id="CD009768-sec-0070"> <h5 class="title">Study outcomes</h5> <p>Clearly defined primary outcomes were reported in seven trials. In three trials of MSCs given as prophylaxis for GvHD, the primary outcome was defined as incidence of GvHD (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>), or incidence and severity of aGvHD (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>) or cGvHD (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>). Additional primary outcomes in one trial were defined as time to engraftment and safety/tolerability of MSC co‐infusion (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>). In four trials in which MSCs were administered as treatment for aGvHD, the primary outcome in three trials was defined as overall response (including complete and partial response) by day 28 (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), or complete response of at least 28 days duration (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>); the primary outcome in the fourth trial was safety (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> <p>Secondary outcomes were defined in seven studies (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) and included safety of MSC infusion, overall survival, event‐free or disease‐free survival, disease relapse, incidence of acute or chronic GvHD, infection rates, time to engraftment, complete/partial/overall response of GvHD and time to response. </p> <p>Five studies failed to define primary or secondary outcomes (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). Study‐specific reported outcomes are listed in the <a href="./references#CD009768-sec-0136" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD009768-sec-0071"> <h5 class="title">Study funding</h5> <p>Nine trials reported the source of funding. Three trials were commercially sponsored by Osiris Therapeutics, Inc. (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), and six trials were supported by national government or academic research funding (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). No details of study funding were reported in the remaining three trials (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> </section> <section id="CD009768-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>We identified 13 ongoing trials (<a href="./references#CD009768-bbs2-0043" title="ACTRN12608000129381 . Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high‐risk acute leukemia: to reduce the severity of graft versus host disease and relapse. http://www.anzctr.org.au/ACTRN12608000129381.aspx (first received 13 March 2008). ">ACTRN12608000129381</a>; <a href="./references#CD009768-bbs2-0044" title="ChiCTR‐IIR‐16007806 . Clincal study of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transpantation‐‐multicenter, randomized parallel controlled, double‐blind trial. http://www.chictr.org.cn/showproj.aspx?proj=13052 (first received 20 January 2016). ">ChiCTR‐IIR‐16007806</a>; <a href="./references#CD009768-bbs2-0045" title="ChiCTR‐INR‐16008399 . Cotransplantation of haploidentical peripheral blood stem cells and mesenchymal stem cells for acute leukemia: a randomized, controlled clinical study. http://www.chictr.org.cn/showproj.aspx?proj=14141 (first received 1 May 2016). ">ChiCTR‐INR‐16008399</a>; <a href="./references#CD009768-bbs2-0046" title="EUCTR2008‐005594‐35‐BE . Randomized double‐blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation‐ A European multicentre study. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐005594‐35/BE (first received 6 August 2009). ">EUCTR2008‐005594‐35‐BE</a>; <a href="./references#CD009768-bbs2-0047" title="EUCTR2009‐014980‐38‐BE . Co‐transplantation of mesenchymal stem cells and HLA‐mismatched allogeneic hematopoietic cells after reduced‐intensity conditioning: a phase II randomized double‐blind study. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2009‐014980‐38/BE (first received 26 January 2010). ">EUCTR2009‐014980‐38‐BE</a>; <a href="./references#CD009768-bbs2-0048" title="EUCTR2011‐003237‐33‐NL . Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids. A prospective double‐blind placebo‐controlled randomized phase III trial. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2011‐003237‐33/NL (first received 15 August 2013). ">EUCTR2011‐003237‐33‐NL</a>; <a href="./references#CD009768-bbs2-0049" title="EUCTR2012‐004915‐30‐NL . Treatment of severe steroid‐refractory acute GvHD with mesenchymal stromal cells.. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐004915‐30/NL (first received 30 January 2013). ">EUCTR2012‐004915‐30‐NL</a>; <a href="./references#CD009768-bbs2-0050" title="ChiCTR‐TRC‐09000536 . A phase II, randomized study to evaluate the safety and efficacy of ex‐vivo cultured allogenic mesenchymal stem cells for the treatment of extensive chronic graft versus host disease. http://www.chictr.org.cn/showproj.aspx?proj=8999 (first received 28 September 2009). NCT00972660 . Safety and efficacy study of allogenic mesenchymal stem cells to treat extensive chronic graft versus host disease [A phase II, randomized study to evaluate the safety and efficacy of ex‐vivo cultured allogenic mesenchymal stem cells for the treatment of extensive chronic graft versus host disease]. clinicaltrials.gov/show/NCT00972660 (first received 4 September 2009). ">NCT00972660</a>; <a href="./references#CD009768-bbs2-0051" title="NCT01045382 . MSC and HSC coinfusion in mismatched minitransplants [Co‐transplantation of mesenchymal stem cells and HLA‐mismatched allogeneic hematopoietic cells after nonmyeloablative conditioning: a phase II randomized double‐blind study]. clinicaltrials.gov/show/NCT01045382 (first received 8 January 2010). ">NCT01045382</a>; <a href="./references#CD009768-bbs2-0052" title="NCT01589549 . Mesenchymal stromal cells for acute graft versus host disease [A Phase 2 trial of standard of care treatment versus mesenchymal stromal cell therapy together with standard of care for the treatment of de novo acute graft versus host disease following allogeneic bone marrow transplantation]. clinicaltrials.gov/show/NCT01589549 (first received 26 April 2012). ">NCT01589549</a>; <a href="./references#CD009768-bbs2-0053" title="NCT02241018 . MSCs combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid‐resistant aGVHD [Mesenchymal stem cells combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid‐resistant acute graft‐versus‐host disease after allogeneic stem cell transplantation]. clinicaltrials.gov/show/NCT02241018 (first received 13 September 2014). ">NCT02241018</a>; <a href="./references#CD009768-bbs2-0054" title="NCT02291770 . Treatment of chronic graft‐versus‐host disease with mesenchymal stromal cells (MSC‐cGvHD) [Treatment of chronic graft‐versus‐host disease with mesenchymal stromal cells. A phase III randomized open label multi‐center study in Southern China.]. clinicaltrials.gov/show/NCT02291770 (first received 5 November 2014). ">NCT02291770</a>; <a href="./references#CD009768-bbs2-0055" title="NCT02770430 . Mesenchymal stem cells as first treatment line for resistant acute graft versus host disease [A phase II, randomized study to evaluate the human mesenchymal stem cells as a first‐line treatment for aGVHD in patients steroids resistant]. clinicaltrials.gov/show/NCT02770430 (first received 8 October 2015). ">NCT02770430</a>) (see <a href="./references#CD009768-sec-0139" title="">Characteristics of ongoing studies</a> for full details). </p> <p>Six trials administer MSCs as GvHD prophylaxis (<a href="./references#CD009768-bbs2-0043" title="ACTRN12608000129381 . Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high‐risk acute leukemia: to reduce the severity of graft versus host disease and relapse. http://www.anzctr.org.au/ACTRN12608000129381.aspx (first received 13 March 2008). ">ACTRN12608000129381</a>; <a href="./references#CD009768-bbs2-0044" title="ChiCTR‐IIR‐16007806 . Clincal study of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transpantation‐‐multicenter, randomized parallel controlled, double‐blind trial. http://www.chictr.org.cn/showproj.aspx?proj=13052 (first received 20 January 2016). ">ChiCTR‐IIR‐16007806</a>; <a href="./references#CD009768-bbs2-0045" title="ChiCTR‐INR‐16008399 . Cotransplantation of haploidentical peripheral blood stem cells and mesenchymal stem cells for acute leukemia: a randomized, controlled clinical study. http://www.chictr.org.cn/showproj.aspx?proj=14141 (first received 1 May 2016). ">ChiCTR‐INR‐16008399</a>; <a href="./references#CD009768-bbs2-0046" title="EUCTR2008‐005594‐35‐BE . Randomized double‐blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation‐ A European multicentre study. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐005594‐35/BE (first received 6 August 2009). ">EUCTR2008‐005594‐35‐BE</a>; <a href="./references#CD009768-bbs2-0047" title="EUCTR2009‐014980‐38‐BE . Co‐transplantation of mesenchymal stem cells and HLA‐mismatched allogeneic hematopoietic cells after reduced‐intensity conditioning: a phase II randomized double‐blind study. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2009‐014980‐38/BE (first received 26 January 2010). ">EUCTR2009‐014980‐38‐BE</a>; <a href="./references#CD009768-bbs2-0051" title="NCT01045382 . MSC and HSC coinfusion in mismatched minitransplants [Co‐transplantation of mesenchymal stem cells and HLA‐mismatched allogeneic hematopoietic cells after nonmyeloablative conditioning: a phase II randomized double‐blind study]. clinicaltrials.gov/show/NCT01045382 (first received 8 January 2010). ">NCT01045382</a>) and seven trials give MSCs as treatment for ether acute or chronic GvHD (<a href="./references#CD009768-bbs2-0048" title="EUCTR2011‐003237‐33‐NL . Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids. A prospective double‐blind placebo‐controlled randomized phase III trial. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2011‐003237‐33/NL (first received 15 August 2013). ">EUCTR2011‐003237‐33‐NL</a>; <a href="./references#CD009768-bbs2-0049" title="EUCTR2012‐004915‐30‐NL . Treatment of severe steroid‐refractory acute GvHD with mesenchymal stromal cells.. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐004915‐30/NL (first received 30 January 2013). ">EUCTR2012‐004915‐30‐NL</a>; <a href="./references#CD009768-bbs2-0050" title="ChiCTR‐TRC‐09000536 . A phase II, randomized study to evaluate the safety and efficacy of ex‐vivo cultured allogenic mesenchymal stem cells for the treatment of extensive chronic graft versus host disease. http://www.chictr.org.cn/showproj.aspx?proj=8999 (first received 28 September 2009). NCT00972660 . Safety and efficacy study of allogenic mesenchymal stem cells to treat extensive chronic graft versus host disease [A phase II, randomized study to evaluate the safety and efficacy of ex‐vivo cultured allogenic mesenchymal stem cells for the treatment of extensive chronic graft versus host disease]. clinicaltrials.gov/show/NCT00972660 (first received 4 September 2009). ">NCT00972660</a>; <a href="./references#CD009768-bbs2-0052" title="NCT01589549 . Mesenchymal stromal cells for acute graft versus host disease [A Phase 2 trial of standard of care treatment versus mesenchymal stromal cell therapy together with standard of care for the treatment of de novo acute graft versus host disease following allogeneic bone marrow transplantation]. clinicaltrials.gov/show/NCT01589549 (first received 26 April 2012). ">NCT01589549</a>; <a href="./references#CD009768-bbs2-0053" title="NCT02241018 . MSCs combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid‐resistant aGVHD [Mesenchymal stem cells combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid‐resistant acute graft‐versus‐host disease after allogeneic stem cell transplantation]. clinicaltrials.gov/show/NCT02241018 (first received 13 September 2014). ">NCT02241018</a>; <a href="./references#CD009768-bbs2-0054" title="NCT02291770 . Treatment of chronic graft‐versus‐host disease with mesenchymal stromal cells (MSC‐cGvHD) [Treatment of chronic graft‐versus‐host disease with mesenchymal stromal cells. A phase III randomized open label multi‐center study in Southern China.]. clinicaltrials.gov/show/NCT02291770 (first received 5 November 2014). ">NCT02291770</a>; <a href="./references#CD009768-bbs2-0055" title="NCT02770430 . Mesenchymal stem cells as first treatment line for resistant acute graft versus host disease [A phase II, randomized study to evaluate the human mesenchymal stem cells as a first‐line treatment for aGVHD in patients steroids resistant]. clinicaltrials.gov/show/NCT02770430 (first received 8 October 2015). ">NCT02770430</a>). </p> <p>Two trials have a planned follow‐up of 10 years and are due to be completed in 2023 (<a href="./references#CD009768-bbs2-0048" title="EUCTR2011‐003237‐33‐NL . Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids. A prospective double‐blind placebo‐controlled randomized phase III trial. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2011‐003237‐33/NL (first received 15 August 2013). ">EUCTR2011‐003237‐33‐NL</a>; <a href="./references#CD009768-bbs2-0049" title="EUCTR2012‐004915‐30‐NL . Treatment of severe steroid‐refractory acute GvHD with mesenchymal stromal cells.. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐004915‐30/NL (first received 30 January 2013). ">EUCTR2012‐004915‐30‐NL</a>). Five other trials with planned follow‐up ranging from 100 days to two years are due to be completed in December 2017 (<a href="./references#CD009768-bbs2-0050" title="ChiCTR‐TRC‐09000536 . A phase II, randomized study to evaluate the safety and efficacy of ex‐vivo cultured allogenic mesenchymal stem cells for the treatment of extensive chronic graft versus host disease. http://www.chictr.org.cn/showproj.aspx?proj=8999 (first received 28 September 2009). NCT00972660 . Safety and efficacy study of allogenic mesenchymal stem cells to treat extensive chronic graft versus host disease [A phase II, randomized study to evaluate the safety and efficacy of ex‐vivo cultured allogenic mesenchymal stem cells for the treatment of extensive chronic graft versus host disease]. clinicaltrials.gov/show/NCT00972660 (first received 4 September 2009). ">NCT00972660</a>), December 2018 (<a href="./references#CD009768-bbs2-0053" title="NCT02241018 . MSCs combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid‐resistant aGVHD [Mesenchymal stem cells combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid‐resistant acute graft‐versus‐host disease after allogeneic stem cell transplantation]. clinicaltrials.gov/show/NCT02241018 (first received 13 September 2014). ">NCT02241018</a>; <a href="./references#CD009768-bbs2-0055" title="NCT02770430 . Mesenchymal stem cells as first treatment line for resistant acute graft versus host disease [A phase II, randomized study to evaluate the human mesenchymal stem cells as a first‐line treatment for aGVHD in patients steroids resistant]. clinicaltrials.gov/show/NCT02770430 (first received 8 October 2015). ">NCT02770430</a>), December 2019 (<a href="./references#CD009768-bbs2-0054" title="NCT02291770 . Treatment of chronic graft‐versus‐host disease with mesenchymal stromal cells (MSC‐cGvHD) [Treatment of chronic graft‐versus‐host disease with mesenchymal stromal cells. A phase III randomized open label multi‐center study in Southern China.]. clinicaltrials.gov/show/NCT02291770 (first received 5 November 2014). ">NCT02291770</a>) and July 2023 (<a href="./references#CD009768-bbs2-0051" title="NCT01045382 . MSC and HSC coinfusion in mismatched minitransplants [Co‐transplantation of mesenchymal stem cells and HLA‐mismatched allogeneic hematopoietic cells after nonmyeloablative conditioning: a phase II randomized double‐blind study]. clinicaltrials.gov/show/NCT01045382 (first received 8 January 2010). ">NCT01045382</a>). One trial was due to have been completed in December 2016 (<a href="./references#CD009768-bbs2-0052" title="NCT01589549 . Mesenchymal stromal cells for acute graft versus host disease [A Phase 2 trial of standard of care treatment versus mesenchymal stromal cell therapy together with standard of care for the treatment of de novo acute graft versus host disease following allogeneic bone marrow transplantation]. clinicaltrials.gov/show/NCT01589549 (first received 26 April 2012). ">NCT01589549</a>) but no publications relating to this trial have been identified. Five trials have not reported an expected completion date (<a href="./references#CD009768-bbs2-0043" title="ACTRN12608000129381 . Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high‐risk acute leukemia: to reduce the severity of graft versus host disease and relapse. http://www.anzctr.org.au/ACTRN12608000129381.aspx (first received 13 March 2008). ">ACTRN12608000129381</a>; <a href="./references#CD009768-bbs2-0044" title="ChiCTR‐IIR‐16007806 . Clincal study of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transpantation‐‐multicenter, randomized parallel controlled, double‐blind trial. http://www.chictr.org.cn/showproj.aspx?proj=13052 (first received 20 January 2016). ">ChiCTR‐IIR‐16007806</a>; <a href="./references#CD009768-bbs2-0045" title="ChiCTR‐INR‐16008399 . Cotransplantation of haploidentical peripheral blood stem cells and mesenchymal stem cells for acute leukemia: a randomized, controlled clinical study. http://www.chictr.org.cn/showproj.aspx?proj=14141 (first received 1 May 2016). ">ChiCTR‐INR‐16008399</a>; <a href="./references#CD009768-bbs2-0046" title="EUCTR2008‐005594‐35‐BE . Randomized double‐blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation‐ A European multicentre study. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐005594‐35/BE (first received 6 August 2009). ">EUCTR2008‐005594‐35‐BE</a>; <a href="./references#CD009768-bbs2-0047" title="EUCTR2009‐014980‐38‐BE . Co‐transplantation of mesenchymal stem cells and HLA‐mismatched allogeneic hematopoietic cells after reduced‐intensity conditioning: a phase II randomized double‐blind study. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2009‐014980‐38/BE (first received 26 January 2010). ">EUCTR2009‐014980‐38‐BE</a>). The trialists in the latter two trials have confirmed that these two trials are still ongoing. We have been unable to clarify the progress of the other three trials. </p> <p>The planned enrolment for these 13 trials includes a total of 1532 participants. We will monitor their progress and when they are published, assuming eligibility, we will include them in future updates of the review. </p> </section> </section> <section id="CD009768-sec-0073"> <h4 class="title">Excluded studies</h4> <p>See <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011305.pub2/full#CD011305-sec2-0033" target="_blank">Characteristics of excluded studies</a> for further details. </p> <p>Full‐text screening excluded 28 trials (described in 36 records). Briefly, the reasons for exclusion were non‐randomised treatment allocation (seven trials), single‐arm trial with no control/placebo group (14 trials), intervention not relevant to this review (three trials), incorrect patient population (two trials), pre‐clinical study (1 trial), and one study was withdrawn. </p> <section id="CD009768-sec-0074"> <h5 class="title">Studies awaiting classification</h5> <p>Two studies (<a href="./references#CD009768-bbs2-0041" title="GhavamzadehA , RanjbarH , NikbakhtM , AlimoghaddamK , VaeziM , BaharB , et al. Outcomes of co‐transplantation of mesenchymal stem cells and hematopoietic stem cells compared to hematopoietic stem cell transplantation alone in ‐thalassemia patients. Bone Marrow Transplantation2017;52(Suppl. 1):293. ">Ghavamzadeh 2017</a>; <a href="./references#CD009768-bbs2-0042" title="XiangJF . Effect of human umbilical cord mesenchymal stem cells on immune reconstruction of acute lymphoblastic leukemia children undergoing allogeneic hematopoietic stem cell transplantation. Chinese Journal of Tissue Engineering Research2017;21(29):4679‐84. ">Xiang 2017</a>) were identified during the final search update (December 2018) and have been included in <a href="./references#CD009768-bbs1-0003" title="">Studies awaiting classification</a>, to be incorporated in future updates of this review. Both trials were of MSCs administered prophylactically and included a total of 134 participants (73 MSCs, 61 no MSCs). The first trial (<a href="./references#CD009768-bbs2-0041" title="GhavamzadehA , RanjbarH , NikbakhtM , AlimoghaddamK , VaeziM , BaharB , et al. Outcomes of co‐transplantation of mesenchymal stem cells and hematopoietic stem cells compared to hematopoietic stem cell transplantation alone in ‐thalassemia patients. Bone Marrow Transplantation2017;52(Suppl. 1):293. ">Ghavamzadeh 2017</a>) was reported as a conference abstract and included patients with beta‐thalassaemia although it is unclear whether treatment allocation was randomised. The second trial (<a href="./references#CD009768-bbs2-0042" title="XiangJF . Effect of human umbilical cord mesenchymal stem cells on immune reconstruction of acute lymphoblastic leukemia children undergoing allogeneic hematopoietic stem cell transplantation. Chinese Journal of Tissue Engineering Research2017;21(29):4679‐84. ">Xiang 2017</a>) recruited children with acute lymphoblastic leukaemia. </p> </section> </section> </section> <section id="CD009768-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>See the ’Risk of bias’ tables within <a href="./references#CD009768-sec-0136" title="">Characteristics of included studies</a> for details of our assessment for each study and <a href="#CD009768-fig-0002">Figure 2</a> for a summary. </p> <div class="figure" id="CD009768-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009768-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009768-sec-0076"> <h4 class="title">Allocation</h4> <p>Two trials reported the method of random sequence generation and allocation and were considered to have a low risk of bias (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). In the first (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>), computer‐generated random numbers were used and treatment allocation was retained in a data centre; in the second (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), patients were randomised via a centralised interactive voice recognition system. </p> <p>Three trials reported that they used stratified block randomisation (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>) but the method of random sequence generation and allocation was not reported; the risk of selection bias was considered to be unclear in these trials. An unclear risk of selection bias was also attributed to the remaining seven trials which reported no details of random sequence generation or allocation (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> </section> <section id="CD009768-sec-0077"> <h4 class="title">Blinding</h4> <p>Trial participants were blinded to treatment through the use of a placebo in three trials (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) which were considered to have a low risk of performance bias. A high risk of performance bias was attributed to eight trials, which were described either as open‐label with no blinding attempted (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>) or where no attempt at blinding or use of a placebo was described (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). One trial with an unclear risk of bias was described as "double‐blind" but no details of a placebo were given (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>). </p> <p>Two trials retained full blinding of all personnel until a specified post‐analysis time point (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>); these trials were considered to have a low risk of detection bias. A high risk of bias was attributed to four open‐label trials in which no blinding of outcome assessors was reported (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>). The remaining six trials did not report whether outcome assessors were blinded and in these trials the risk of detection bias was unclear (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> </section> <section id="CD009768-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias was generally low. In four trials, all randomised participants were included in the analysis (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>); five further trials reported withdrawals but these were low in number and reasons for withdrawals or exclusions were given (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>); two trials performed intention‐to‐treat analyses (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). Two trials failed to report the number of randomised participants (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>); these trials were considered to have a high risk of attrition bias. One trial with an unclear risk of attrition bias originally included a randomised control group but this was dropped from the trial after a protocol amendment to a dose‐comparison trial due to inadequate recruitment (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> </section> <section id="CD009768-sec-0079"> <h4 class="title">Selective reporting</h4> <p>Study protocols as defined by clinical trial records were identified for seven trials (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). Of these, two trials reported all outcomes described in the protocol and were therefore considered to have a low risk of reporting bias (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>). </p> <p>Five trials had a high risk of reporting bias as they only reported limited results within a press release (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>) or conference abstract (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). In the <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a> trial, results were extracted from licensing application documents published by the Australian Government Therapeutic Goods Administration; however not all outcome results were reported therein. A high risk of reporting bias was also attributed to one trial which was terminated early due to a higher median time to disease relapse in patients who received MSCs than in the control group (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>). </p> <p>An unclear risk of reporting bias was attributed to two trials in which all outcomes in the protocol were reported, but the time points at which outcomes were measured differed to those described in the protocol (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>). Finally, two trials reported all outcomes described in the methods; however no study protocol was identified to fully assess selective reporting and therefore the risk of reporting bias was unclear <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). </p> </section> <section id="CD009768-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>One trial was considered to be at a high risk of bias as no publications relating to this trial were identified other than a press release containing very few details (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>); there is no indication that this trial will be published in the future. One ongoing trial started in 2008 (<a href="./references#CD009768-bbs2-0043" title="ACTRN12608000129381 . Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high‐risk acute leukemia: to reduce the severity of graft versus host disease and relapse. http://www.anzctr.org.au/ACTRN12608000129381.aspx (first received 13 March 2008). ">ACTRN12608000129381</a>) has not as yet been published and we have been unable to establish the current status of this trial. We therefore consider that there is a risk of publication bias. </p> <p>An unclear risk of bias was attributed to five trials due to various factors. Two trials (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>) included patients who received haematopoietic stem cells which originated from either bone marrow or peripheral blood but did not provide any information on the number of participants in each trial arm who received each graft type. Engraftment and GvHD rates can differ depending on the source of haematopoietic stem cells and there may be a risk of bias due to differences between trial arms. Two trials (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), which were published in abstract form only did not provide sufficient information to adequately assess additional sources of bias. Finally, for one trial data were extracted from licensing application documents published by the Australian Government Therapeutic Goods Administration which may contribute an additional source of bias (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). </p> </section> </section> <section id="CD009768-sec-0081"> <h3 class="title" id="CD009768-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD009768-tbl-0001"><b>Summary of findings for the main comparison</b> MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity</a> </p> <p>Results are presented separately below for the comparison of <b>:</b> mesenchymal stromal cells (MSCs) versus no MSCs, and for the comparison of different doses of MSCs. We identified 10 trials that compared the use of MSCs with no MSCs, and two trials that compared two different doses of MSCs. We did not identify any trials that compared different sources of MSCs. </p> <p>For the primary outcomes of mortality and safety, and the secondary outcomes or adverse events, health‐related quality of life, relapse of malignant disease infection rates and engraftment, results are presented for prophylactic and therapeutic trials combined. Subgroup analyses are used to assess differences between prophylactic and therapeutic trials where relevant. </p> <section id="CD009768-sec-0082"> <h4 class="title">Use of MSCs versus no MSC treatment</h4> <p>Ten trials compared MSCs with a control or placebo group (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) (see <a href="#CD009768-tbl-0002">Table 1</a>; <a href="#CD009768-tbl-0003">Table 2</a>) for a summary of participant characteristics and interventions). These 10 trials comprised a total of 833 randomised participants, including 372 randomised to MSCs and 269 randomised to the control group (one trial only reported the number analysed (included in these totals) (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>) and in one trial the number randomised to each treatment arm was not reported (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>)). The main results for this comparison are shown in <a href="./full#CD009768-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD009768-sec-0083"> <h5 class="title">Primary Outcomes</h5> <section id="CD009768-sec-0084"> <h6 class="title">All‐cause mortality</h6> <p>Nine trials measured mortality (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), although one trial did not report results for this outcome (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>) and in one trial, mortality was reported as percentage overall survival but it was unclear as to what these values represented (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>). Of the remaining seven trials, five gave MSCs as prophylaxis (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>) and two gave MSCs as treatment for GvHD (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). Log hazard ratios with standard errors were estimated either using the methods of (<a href="./references#CD009768-bbs2-0079" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD009768-bbs2-0085" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>), method 7 (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>) or method 9 (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), or from individual patient data presented in the trial publications (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). One trial provided insufficient data to estimate log hazard ratios (<a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> <p>Analysis of mortality was considered to be inappropriate for treatment and prophylaxis trials pooled. Subgroup analysis showed insufficient evidence to detect a difference in the risk of mortality in either prophylactic trials (HR 0.85, 95% CI 0.50 to 1.42; participants = 301; studies = 5; I<sup>2</sup> = 34%; low‐quality evidence) or therapeutic trials HR 1.12, 95% CI 0.80 to 1.56; participants = 244; studies = 1; <i>v</i>ery low‐quality evidence) (test for subgroup differences: P = 0.38) (<a href="./references#CD009768-fig-0005" title="">Analysis 1.1</a>). No obvious outliers explained the moderate heterogeneity observed for this outcome in the five prophylactic trials. </p> <p>Seven studies reported reasons for mortality (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). In six trials in which MSCs were administered as prophylaxis for GvHD (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), relapse was the most common reason for death, accounting for 71.7% of deaths occurring in the MSC group compared with 58.6% in the control group. In the GvHD treatment trial (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), the most frequent reason for death was infections/infestations, followed by immune system disorders and GvHD. </p> </section> <section id="CD009768-sec-0085"> <h6 class="title">Safety of MSC infusion – acute toxicity, ectopic tissue formation or oncogenesis</h6> <p>Seven trials encompassing a total of 593 participants (334 MSCs, 259 no MSCs) reported measures of safety of MSC infusion (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). Results were presented descriptively in all seven trials. MSCs were well‐tolerated in all trials, with no incidences of acute toxicity, ectopic tissue formation or oncogenesis reported in any study. </p> </section> </section> <section id="CD009768-sec-0086"> <h5 class="title">Secondary Outcomes</h5> <section id="CD009768-sec-0087"> <h6 class="title">Health‐related quality of life using validated scale</h6> <p>No trial reported health‐related quality of life measures. One therapeutic trial (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) described quote: "change from baseline in quality of life and Karnofsky/Lansky Performance Status assessments" as an additional efficacy variable of interest, but no results were reported for this outcome. One trial included quality of life in their protocol but no results for this outcome were reported (<a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>). </p> </section> <section id="CD009768-sec-0088"> <h6 class="title">Relapse of malignant disease</h6> <p>Two therapeutic trials reported relapse of malignant disease at short‐term follow‐up (≤ 12 months) (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) (measured at 90 days and 180 days, respectively). There was insufficient evidence to detect a difference in the risk of relapse of malignant disease at short‐term follow‐up in the comparison of MSCs and no MSCs (RR 0.83, 95% CI 0.37 to 1.84; participants = 275; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD009768-fig-0006" title="">Analysis 1.2</a>). </p> <p>Six prophylaxis trials reported relapse of malignant disease at long‐term follow‐up (&gt; 12 months) (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). There was insufficient evidence to detect a difference in the risk of relapse of malignant disease at long‐term follow‐up in the comparison of MSCs and no MSCs (RR 1.08, 95% CI 0.73 to 1.59; participants = 323; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD009768-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD009768-sec-0089"> <h6 class="title">Infection rates</h6> <p>Six studies reported infection as an outcome (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). Two studies reported results descriptively and stated that they observed either no differences in infectious complications (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>), or a similar cumulative incidence of infections in both groups (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>). Four studies <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>) reported incidences of cytomegalovirus (CMV) infection, although in one study it was unclear whether any incidence of CMV infection was observed in the control group (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>). There was insufficient evidence to detect a difference in the risk of CMV infection in the comparison of MSCs and no MSCs (RR 1.03, 95% CI 0.71 to 1.50; participants = 100; studies = 3; I<sup>2</sup> = 0%) (<a href="./references#CD009768-fig-0007" title="">Analysis 1.3</a>). Three trials reported episodes of both bacterial and viral infections (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), although no trial reported significant differences between groups. Meta‐analysis of these trials was not possible due to overlap in reporting of different infections across patients. </p> </section> <section id="CD009768-sec-0090"> <h6 class="title">Engraftment</h6> <p>Engraftment was reported in five trials (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). The time to engraftment of platelets and neutrophils is summarised in <a href="#CD009768-tbl-0004">Table 3</a>. The times were similar between the trial arms except for the cord blood HSCT study of <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>, where both platelets and neutrophils engrafted at significantly faster rates with MSC treatment (P = 0.004 and P = 0.003, respectively). Two trials (<a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>) were observed to have high neutrophil engraftment times in the control group. In the case of <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>, the HSCT source was cord blood which is known to lead to longer engraftment times. Therefore, this could potentially demonstrate a reduced engraftment time in patients who receive MSCs in this subgroup. </p> <div class="table" id="CD009768-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Engraftment of platelets and neutrophils</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>MSC dose/schedule</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Definition of platelet engraftment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to platelet engraftment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Definition of neutrophil engraftment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to neutrophil engraftment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSCs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No MSCs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSCs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No MSCs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45‐1.8 x 10<sup>6</sup> cells/kg given in single intravenous infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 20 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 16 days (range n/r)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 15 days (range n/r)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 14 days (range n/r)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 13 days (range n/r)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐5 x 10<sup>5</sup> cells/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;20 x 10<sup>9</sup>/L for 7 consecutive days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 19.5 (range 8‐52) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 20 (range 10‐80) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L for 3 consecutive days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 12 (range 10‐21) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 12 (range 10‐23) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 +/‐ 0.4 x 10<sup>6</sup> cells/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 18 (range 10‐44) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 23 (range 16‐144) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 19 (range 12‐20) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 24 (range 16‐45) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 3.3 (range 0.3‐15.3) x 10<sup>5</sup> cells/kg given intravenously over 30 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 x 10<sup>9</sup>/L (first of 3 consecutive days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 30 (range 16‐45) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 27 (15‐64) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L (first of 3 consecutive days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 16 (range 12‐21) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 15 (range 11‐20) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 7.19 (range 2.44 to 10.12) x 10<sup>6</sup> cells/kg infused over 30 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 20 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 30 (range 20‐45) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 73 (42‐135) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 12 (range 8‐16) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 21 (range 17‐43) days</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n/r not reported</p> </div> </div> </section> <section id="CD009768-sec-0091"> <h6 class="title">Incidence of acute GvHD (prophylactic trials only)</h6> <p>Six trials reported the incidence of acute GvHD, classified as grades I to II (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>), grades I to III (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>), grades I to IV (<a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>), grades II to IV (<a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>) and undefined in one trial (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>). There was insufficient evidence to detect a difference in the risk of acute GvHD in the comparison of MSCs and no MSCs (RR 0.86, 95% CI 0.63 to 1.17; participants = 247; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD009768-fig-0008" title="">Analysis 1.4</a>) (<a href="#CD009768-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD009768-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.4 Incidence of aGvHD (prophylactic trials)." data-id="CD009768-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.4 Incidence of aGvHD (prophylactic trials). </p> </div> </div> </div> <p>Subgroup analysis according to type of disease (malignant versus non‐malignant) revealed no differences between groups (test for subgroup differences: P = 0.39) (malignant disease: RR 0.83, 95% CI 0.60 to 1.14; participants = 199; studies = 5; non‐malignant disease: RR 1.38, 95% CI 0.45 to 4.28; participants = 48; studies = 1) (<a href="./references#CD009768-fig-0018" title="">Analysis 3.1</a>). </p> </section> <section id="CD009768-sec-0092"> <h6 class="title">Incidence of chronic GvHD (prophylactic trials only)</h6> <p>Six trials reported the incidence of chronic GvHD (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). Meta‐analysis of these trials showed evidence that the risk of developing chronic GvHD was reduced in recipients of MSCs when compared to those who received no MSCs (RR 0.66, 95% CI 0.49 to 0.89; participants = 283; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD009768-fig-0009" title="">Analysis 1.5</a>) (<a href="#CD009768-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009768-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.5 Incidence of cGvHD (prophylactic trials)." data-id="CD009768-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.5 Incidence of cGvHD (prophylactic trials). </p> </div> </div> </div> </section> <section id="CD009768-sec-0093"> <h6 class="title">Complete and partial response (therapeutic trials only)</h6> <p>Three trials measured complete and/or partial response of GvHD to treatment (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) although one trial did not report results for this outcome (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>). </p> <p>In one trial which measured aGvHD response (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), there was no evidence of a difference between treatment arms in either complete response in the whole study cohort (RR 1.16, 95% CI 0.79 to 1.70; participants = 260, studies = 1; <i>v</i>ery low‐quality evidence) (<a href="./references#CD009768-fig-0010" title="">Analysis 1.6</a>), or partial response reported in a paediatric subgroup (RR 2.00, 95% CI 0.20 to 19.6; participants = 28, studies = 1) (<a href="./references#CD009768-fig-0011" title="">Analysis 1.7</a>). </p> <p>In one trial which measured cGvHD response (<a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>), an "excellent response" was observed in 15/30 patients who received MSCs compared with 1/10 patients in the comparator group, with no evidence of a difference between treatment arms (RR 5.00, 95% CI 0.75 to 33.21, participants = 40, studies = 1; <i>v</i>ery low‐quality evidence) (<a href="./references#CD009768-fig-0012" title="">Analysis 1.8</a>). The equivalent number of participants who showed a partial response to treatment was 12/30 compared to 3/10 (RR 2.00, 95% CI 0.54 to 7.45, participants = 40, studies = 1) (<a href="./references#CD009768-fig-0013" title="">Analysis 1.9</a>). </p> </section> </section> </section> <section id="CD009768-sec-0094"> <h4 class="title">Use of MSCs, dose A versus dose B</h4> <p>Two trials compared different doses of MSCs. One trial of 32 randomised participants compared 2 x 10<sup>6</sup> cells/kg with a higher dose of 8 x 10<sup>6</sup> cells/kg (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), and one trial of 17 randomised patients compared 1 x 10<sup>6</sup> cells/kg with a higher dose of 3 x 10<sup>6</sup> cells/kg (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>) (see <a href="#CD009768-tbl-0002">Table 1</a>; <a href="#CD009768-tbl-0003">Table 2</a> for a summary of participant characteristics and interventions). </p> <section id="CD009768-sec-0095"> <h5 class="title">Primary Outcomes</h5> <section id="CD009768-sec-0096"> <h6 class="title">All‐cause mortality</h6> <p>In the <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a> trial, nine deaths occurred in 31 randomised participants; the number of deaths in each treatment arm was not reported. The cause of death was reported as progressive GvHD (4), disease relapse (1), central nervous system bleed (1), pneumonia (1), meningitis (1), and aspergillus enteritis (1). In the second trial (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>), three deaths occurred in the low dose (1 x 10<sup>6</sup> cells/kg) group, all of which were due to progressive chronic GVHD. No deaths occurred in the control group. </p> </section> <section id="CD009768-sec-0097"> <h6 class="title">Safety of MSC infusion – acute toxicity, ectopic tissue formation or oncogenesis</h6> <p>In both trials, all infusions were generally well‐tolerated with no acute infusional toxicity and no ectopic tissue formation (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>; <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>). Three participants were reported with adverse events related to intravenous drug infusion: one with pruritus on face, trunk and legs, one with high blood pressure and one with phlebitis and vein thrombosis of the upper left arm: all three recovered without sequelae (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> </section> </section> <section id="CD009768-sec-0098"> <h5 class="title">Secondary Outcomes</h5> <section id="CD009768-sec-0099"> <h6 class="title">Health‐related quality of life using validated scale</h6> <p>This outcome was not reported.</p> </section> <section id="CD009768-sec-0100"> <h6 class="title">Relapse of malignant disease</h6> <p>In one trial (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>), one disease relapse resulting in death occurred during the first 90 days in the high‐dose MSC group. Two further relapses occurred over long‐term follow‐up but the treatment dose received by these two participants was not reported. No cases of disease relapse were reported in the second trial (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> </section> <section id="CD009768-sec-0101"> <h6 class="title">Infection rates</h6> <p>In the <a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a> trial, infections were reported but the number of infections was not given separately for each treatment arm. Overall, 12 grade three infections (one adenovirus, four bacteraemia, five CMV viraemia and two BK virus‐associated cystitis) and three grade four infections (pseudomonal pneumonia, enterococcal meningitis and aspergillus enteritis) were reported. Infections were also reported in the <a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a> trial in all but two patients in the low cell dose treatment arm, including viral infections (influenza A, CMV, parvovirus, herpes simplex, herpes zoster, Epstein‐Barr, rotavirus) and bacterial infections (cutaneous infection, <i>Clostridium difficile</i> diarrhoea, <i>Campylobacter jejuni</i> diarrhoea). </p> </section> <section id="CD009768-sec-0102"> <h6 class="title">Engraftment</h6> <p>This outcome was not reported.</p> </section> <section id="CD009768-sec-0103"> <h6 class="title">Incidence of acute GvHD (prophylactic trials only)</h6> <p>No prophylactic trials were identified for this comparison.</p> </section> <section id="CD009768-sec-0104"> <h6 class="title">Incidence of chronic GvHD (prophylactic trials only)</h6> <p>No prophylactic trials were identified for this comparison.</p> </section> <section id="CD009768-sec-0105"> <h6 class="title">Complete and partial response (therapeutic trials only)</h6> <p>In one trial there was no evidence of a difference between dosage groups in the proportion of participants with complete response (RR 0.76, 95% CI 0.51 to 1.14; participants = 31; studies = 1) (<a href="./references#CD009768-fig-0015" title="">Analysis 2.2</a>) or partial response of acute GvHD (grades II to IV) to treatment (RR 11.69, 95% CI 0.70 to 194.79; participants = 31; studies = 1) (<a href="./references#CD009768-fig-0016" title="">Analysis 2.3</a>) (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>). There was also no evidence of a difference between dosage groups in the proportion of patients with a complete response to chronic GVHD (RR 0.93, 95% CI 0.37 to 2.33; participants = 14; studies = 1) (<a href="./references#CD009768-fig-0017" title="">Analysis 2.4</a>) (<a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009768-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009768-sec-0106"></div> <p>The main objective of this review was to examine the evidence for the safety and efficacy of mesenchymal stromal cells (MSC) for treating immune‐mediated inflammation post‐transplantation of haematopoietic stem cells. </p> <section id="CD009768-sec-0107"> <h3 class="title" id="CD009768-sec-0107">Summary of main results</h3> <p>The available evidence from these trials showed that:</p> <p> <ul id="CD009768-list-0012"> <li> <p>Prophylactic administration of MSCs in conjunction with HSCT may reduce the risk of developing chronic graft‐versus‐host disease (cGvHD) when compared to no MSCs (RR 0.66, 95% CI 0.49 to 0.89; participants = 283; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). </p> </li> </ul> <ul id="CD009768-list-0013"> <li> <p>MSCs may make little or no difference to the risk of mortality (prophylactic trials: HR 0.85, 95% CI 0.50 to 1.42; participants = 301; studies = 5; <i>l</i>ow‐quality evidence; therapeutic trials: HR 1.12, 95% CI 0.80 to 1.56; participants = 244; studies = 1; very low‐quality evidence), or disease relapse (prophylactic trials: RR 1.08, 95% CI 0.73 to 1.59; participants = 323; studies = 6; low‐quality evidence) compared to no MSCs . </p> </li> </ul> <ul id="CD009768-list-0014"> <li> <p>MSCs may make little or no difference to the risk of acute GvHD compared to no MSCs when administered prophylactically (RR 0.86, 95% CI 0.63 to 1.17; participants = 247; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). </p> </li> </ul> <ul id="CD009768-list-0015"> <li> <p>We are very uncertain whether administration of MSCs improves complete response (CR) (RR 1.16, 95% CI 0.79 to 1.70; participants = 260, studies = 1; <i>v</i>ery low‐quality evidence) or partial response (RR 2.00, 95% CI 0.20 to 19.6; participants = 28, studies = 1) of acute GvHD compared to no MSCs when administered prophylactically. </p> </li> </ul> <ul id="CD009768-list-0016"> <li> <p>We are very uncertain whether administration of MSCs improves complete response (RR 5.00, 95% CI 0.75 to 33.21, participants = 40, studies = 1; very low‐quality evidence) or partial response (RR 2.00, 95% CI 0.54 to 7.45, participants = 40, studies = 1) of chronic GvHD compared to no MSCs when administered prophylactically. </p> </li> </ul> <ul id="CD009768-list-0017"> <li> <p>We are very uncertain whether a higher dose of MSCs reduces the risk of malignant disease relapse or complete (RR 0.76, 95% CI 0.51 to 1.14; participants = 31; studies = 1) or partial response (RR 11.69, 95% CI 0.70 to 194.79; participants = 31; studies = 1) to acute GvHD. </p> </li> </ul> </p> </section> <section id="CD009768-sec-0108"> <h3 class="title" id="CD009768-sec-0108">Overall completeness and applicability of evidence</h3> <p>This review provides the most up‐to‐date evidence for the role of MSCs as treatment or prophylaxis for GvHD in individuals who have received a haematopoietic stem cell transplant (HSCT) for a haematological condition. We identified 12 randomised trials which met the inclusion criteria for this review: 10 trials compared MSCs to no MSCs (control or placebo) involving a total of 833 randomised participants, and two trials of 47 randomised participants compared different doses of MSCs. One trial was in patients with thalassaemia, the remaining 11 trials were in patients with haematological malignancies. Seven trials administered MSCs as a prophylactic intervention for GvHD, whereas five trials gave MSCs as treatment for GvHD. MSCs were derived from umbilical cord in two trials, bone marrow in seven trials and adipose tissue in one trial; two trials failed to report the origin of MSCs. In the comparison of MSCs with no MSCs, cells were administered at a dose of between 10<sup>5</sup> and 10<sup>7</sup> cells/kg in either a single dose (six trials) or in multiple doses (four trials). The dose‐comparison trials compared 2 x 10<sup>6</sup> cells/kg with 8 x 10<sup>6</sup> cells/kg in two infusions, or 1 x 10<sup>6</sup> cells/kg with 3 x 10<sup>6</sup> cells/kg in a single infusion. The median duration of follow‐up in seven trials which administered MSCs prophylactically ranged from 10 months to 60 months. In three trials of MSCs as treatment for acute GvHD,(aGvHD), participants were followed up for 90 or 100 days. In two trials of MSCs as treatment for cGvHD, the mean duration of follow‐up was 13.4 months (MSC group) and 23.6 months (control group), or 56 weeks. </p> <p>There is a high degree of clinical heterogeneity arising from differences in both participant characteristics and interventions across trials. In particular, differences in the underlying HSCT (source and extent of human leukocyte antigen (HLA) matching) as well as the timing, dosage, source and production protocols of the MSCs administered may all contribute to the expected clinical heterogeneity across these studies. Notably, for many outcomes values of I<sup>2</sup> were 0%. However, I<sup>2</sup> values are known to be underestimated, especially when there are few events or a limited number of studies included in a meta‐analysis (<a href="./references#CD009768-bbs2-0071" title="Huedo‐MedinaTB , Sánchez‐MecaJ , Marín‐MartínezF , BotellaJ . Assessing heterogeneity in meta‐analysis: Q statistic or I2 index?. Psychological Methods2006;11(2):193‐206. ">Huedo‐Medina 2006</a>; <a href="./references#CD009768-bbs2-0072" title="IoannidisJP , PatsopoulosNA , EvangelouE . Assessing heterogeneity in meta‐analysis: Q statistic or I2 index?. BMJ2007;335(7626):914‐6. ">Ioannidis 2007</a>). </p> <p>We only identified two trials comparing different doses of MSCs and we found no trials which compared MSCs from different sources (e.g. bone marrow versus cord). The applicability of evidence is therefore limited when considering the question of whether MSCs of a particular source or dose are efficacious in a specific patient population. Across all outcomes, there is insufficient data to show clearly whether MSCs have a beneficial (or detrimental) effect. </p> <p>One trial (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) suggested that MSCs showed a beneficial effect in a paediatric subgroup and in patients with steroid‐refractory aGvHD occurring in the liver and gut. However, we deemed this trial to have a high risk of reporting bias as it was only reported as a conference abstract and press release. We did not identify a sufficient number of trials to perform our proposed subgroup analysis by participant age (adults versus paediatric) or specific organ involvement. </p> <p>No trial reported quality of life as an outcome.</p> </section> <section id="CD009768-sec-0109"> <h3 class="title" id="CD009768-sec-0109">Quality of the evidence</h3> <p>We have summarised the quality of evidence for the main comparison of MSCs versus no MSCs in the <a href="./full#CD009768-tbl-0001">summary of findings Table for the main comparison</a>. Our GRADE assessment found that the overall quality of evidence was low or very low for all included outcomes; all outcomes were downgraded due to risk of bias and imprecision due to the low number of participants included in the analyses. Only two trials reported clearly their methods of random sequence generation and allocation concealment. Only three trials were adequately blinded with the use of a placebo arm. Finally, a high risk of reporting bias was attributed to six trials: four were published in conference abstract form only (<a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>; <a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a>) (although one (<a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>) was the subject of a detailed licensing application to the Therapeutic Goods Administration of the Australian Government, see (<a href="#CD009768-sec-0115">Acknowledgements</a>)), one was reported as press release only with few details (<a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>), and one trial was terminated early prematurely due to an apparent increased risk of disease relapse in patients who received MSCs (<a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>). The majority of trials included fewer than 100 randomised participants in total and only one trial included over 200 participants, leading to imprecision. </p> <p>Three trials were undertaken by Osiris Therapeutics, Inc. (<a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a>; <a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a>; <a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a>), including the two largest trials included in this review which compared MSCs to no MSCs and the reporting of two of these trials was extremely limited, with a high risk of reporting bias. </p> <p>Publication bias was also considered a possibility due to one ongoing trial which was started in 2008 but has not resulted in any associated publications. </p> <p>There was notable clinical heterogeneity in the stem cell sources used for transplantation, types and stages of malignant disease being treated, definitions of outcomes, as well as differences in study quality. We were unable to perform sensitivity analyses due to the paucity of suitable studies, but these will be addressed in future updates of this review as further randomised controlled studies are published. </p> </section> <section id="CD009768-sec-0110"> <h3 class="title" id="CD009768-sec-0110">Potential biases in the review process</h3> <p>We are not aware of any obvious biases with the review process. We conducted an extensive search, which included ongoing trial databases. We also contacted researchers in the field to identify any further as yet unpublished trials. No restrictions were placed on the language in which the paper was originally published or its publication status. We performed all screening and data extraction in duplicate by two review authors and resolved any discrepancies through discussion. We were unable to perform a formal assessment of publication bias due to the low number of included studies. </p> <p>The outcomes defined in this review were revised from the original protocol in accordance with the change of scope of the review to include trials which administered MSCs as prophylaxis for GvHD as well as those in which MSCs were given therapeutically (see <a href="#CD009768-sec-0134">Differences between protocol and review</a>). These revised outcomes were defined <i>a priori</i> in accordance with our expectations for studies of this nature, and were not biased by the outcomes reported in individual studies. </p> <p>None of the review authors were involved in the included or excluded studies.</p> </section> <section id="CD009768-sec-0111"> <h3 class="title" id="CD009768-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review has been published on the safety of MSCs for clinical use (<a href="./references#CD009768-bbs2-0074" title="LaluMM , McIntyreL , PuglieseC , FergussonD , WinstonBW , MarshallJC , et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta‐analysis of clinical trials. PLOs One2012;7(10):e47559. ">Lalu 2012</a>) and our review is consistent with their finding that MSCs are safe for use in patients. Systematic reviews have been published on the use of MSC for prevention and treatment of GvHD (<a href="./references#CD009768-bbs2-0058" title="ChenX , WangC , YinJ , XuJ , WeiJ , ZhangY . Efficacy of mesenchymal stem cell therapy for steroid‐refractory acute graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. PLOS One2015;10(8):e0136991. ">Chen 2015</a>; <a href="./references#CD009768-bbs2-0068" title="HashmiS , AhmedM , MuradMH , LitzowMR , AdamsRH , BallLM , et al. Survival after mesenchymal stromal cell therapy in steroid‐refractory acute graft‐versus‐host disease: systematic review and meta‐analysis. Lancet Haematology2016;3(1):e45‐52. ">Hashmi 2016</a>; <a href="./references#CD009768-bbs2-0073" title="KallekleivM , LarunL , BruserudØ , HatfieldKJ . Co‐transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. Cytotherapy2016;18(2):172‐85. ">Kallekleiv 2016</a>). These included non‐randomised trials, which were excluded from this review, and the authors restricted their analysis to treatment of aGvHD (<a href="./references#CD009768-bbs2-0058" title="ChenX , WangC , YinJ , XuJ , WeiJ , ZhangY . Efficacy of mesenchymal stem cell therapy for steroid‐refractory acute graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. PLOS One2015;10(8):e0136991. ">Chen 2015</a>; <a href="./references#CD009768-bbs2-0068" title="HashmiS , AhmedM , MuradMH , LitzowMR , AdamsRH , BallLM , et al. Survival after mesenchymal stromal cell therapy in steroid‐refractory acute graft‐versus‐host disease: systematic review and meta‐analysis. Lancet Haematology2016;3(1):e45‐52. ">Hashmi 2016</a>) or to co‐transplantation of MSC and HSC (<a href="./references#CD009768-bbs2-0073" title="KallekleivM , LarunL , BruserudØ , HatfieldKJ . Co‐transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. Cytotherapy2016;18(2):172‐85. ">Kallekleiv 2016</a>). These reviews conclude that, while MSCs appear to be safe and there are some indications of efficacy, there is a need for more prospective, randomised controlled trials (RCTs) to establish whether MSCs convey a significant benefit in the prevention or treatment of aGvHD. Kallekleiv and colleagues found a trend (P = 0.015) towards reduced rates of cGvHD with the prophylactic use of MSCs from analysis of three RCTs also included in our review (<a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a>; <a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a>; <a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a>). In our review we included an additional three RCTs (<a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a>; <a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a>; <a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a>) and also found that MSCs may reduce the risk of chronic GvHD (RR 0.66, 95% CI 0.49 to 0.89; participants = 283; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). A recent systematic review of MSCs for cGvHD prophylaxis (<a href="./references#CD009768-bbs2-0087" title="WangL , ZhuCY , MaDX , GuZY , XuCC , WangFY , et al. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft‐versus‐host disease after allogeneic hematopoietic stem cell transplantation: a meta‐analysis of randomized controlled trials. Annals of Hematology2018;97:1941‐50. ">Wang 2018</a>) included six trials and concluded that MSCs significantly reduced the incidence of cGvHD, with risk estimates similar to those found in this Cochrane Review (RR 0.63, 95% CI 0.46 to 0.86). Wang and colleagues also performed separate analyses for adults and children, and found that this effect was only seen in children, although it should be noted that only two studies were included in each group and there was no significant difference between adults and children, as indicated by the overlapping confidence intervals. We will continue to monitor the available randomised trials and update this review accordingly. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009768-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009768-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009768-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.4 Incidence of aGvHD (prophylactic trials)." data-id="CD009768-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.4 Incidence of aGvHD (prophylactic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.5 Incidence of cGvHD (prophylactic trials)." data-id="CD009768-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 MSCs vs. control/placebo, outcome: 1.5 Incidence of cGvHD (prophylactic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 1 All‐cause mortality." data-id="CD009768-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 2 Relapse of malignant disease." data-id="CD009768-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 2 Relapse of malignant disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 3 Infections." data-id="CD009768-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 3 Infections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 4 Incidence of aGvHD (prophylactic trials)." data-id="CD009768-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 4 Incidence of aGvHD (prophylactic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 5 Incidence of cGvHD (prophylactic trials)." data-id="CD009768-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 5 Incidence of cGvHD (prophylactic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 6 Acute GvHD complete response (therapeutic trials)." data-id="CD009768-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 6 Acute GvHD complete response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 7 Acute GvHD partial response (therapeutic trials)." data-id="CD009768-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 7 Acute GvHD partial response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 8 Chronic GvHD complete response (therapeutic trials)." data-id="CD009768-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 8 Chronic GvHD complete response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 MSCs vs. control/placebo, Outcome 9 Chronic GvHD partial response (therapeutic trials)." data-id="CD009768-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 MSCs vs. control/placebo, Outcome 9 Chronic GvHD partial response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 MSCs high dose vs. low dose, Outcome 1 All‐cause mortality (all trials)." data-id="CD009768-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 MSCs high dose vs. low dose, Outcome 1 All‐cause mortality (all trials).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 MSCs high dose vs. low dose, Outcome 2 Acute GvHD complete response (therapeutic trials)." data-id="CD009768-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 MSCs high dose vs. low dose, Outcome 2 Acute GvHD complete response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 MSCs high dose vs. low dose, Outcome 3 Acute GvHD partial response (therapeutic trials)." data-id="CD009768-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 MSCs high dose vs. low dose, Outcome 3 Acute GvHD partial response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 MSCs high dose vs. low dose, Outcome 4 Chronic GvHD complete response (therapeutic trials)." data-id="CD009768-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 MSCs high dose vs. low dose, Outcome 4 Chronic GvHD complete response (therapeutic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009768-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/urn:x-wiley:14651858:media:CD009768:CD009768-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_t/tCD009768-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 MSCs vs. control/placebo: malignant versus non‐malignant disease, Outcome 1 Incidence of aGvHD (prophylactic trials)." data-id="CD009768-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 MSCs vs. control/placebo: malignant versus non‐malignant disease, Outcome 1 Incidence of aGvHD (prophylactic trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/media/CDSR/CD009768/image_n/nCD009768-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009768-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> MSCs<br/> <b>Comparison:</b> No MSCs (control or placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>control/placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MSCs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality (prophylactic trials)</b> </p> <p>(over duration of trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.85</b> <br/> (0.50 to 1.42)*** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>301<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>326 per 1000**</b><br/> (232 to 460) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality (therapeutic trials)</b> </p> <p>(over duration of trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 1.12</b> (0.80 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>244 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>420 per 1000**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>344 per 1000**</b> </p> <p>(248 to 479)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety of MSC infusion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>334</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MSCs were well‐tolerated, no infusion‐related toxicity or ectopic tissue formation was reported in any study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(no studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse of malignant disease (prophylactic trials)</b> </p> <p>(&gt;12‐month follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>99 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>107 per 1000</b> </p> <p>(35 to 185)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.08</b> </p> <p>(0.73 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>323</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of acute GvHD (prophylactic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.86</b> <br/> (0.63 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>247<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b><br/> (246 to 457) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of chronic GvHD (prophylactic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.66</b> <br/> (0.49 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>283<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>469 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b><br/> (230 to 418) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute GvHD complete response (therapeutic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b> <br/> (0.79 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>260<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/> (236 to 508) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic GvHD complete response (therapeutic trials)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.00</b> <br/> (0.75 to 33.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/> (75 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>GvHD:</b> graft‐versus‐host disease; <b>HR</b> : hazard ratio; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 for high risk of bias due to inclusion of trials that do not report methods of random sequence generation or allocation, are unblinded, or are subject to selective reporting.<br/> <sup>2</sup> Downgraded by 1 for imprecision as the total population size is less than 400 participants. </p> <p><sup>3</sup> Downgraded by 2 for imprecision as the total population size is less than 400 participants and evidence is based on only one study. </p> <p>*The assumed risk is based on the observed rate in controls.</p> <p>**The hazard ratio for all‐cause mortality has been converted to a relative risk to estimate the corresponding risk in the MSC group. </p> <p>*** A hazard ratio less than 1 indicates advantage to MSCs, a value greater than 1 indicates advantage to no MSCs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009768-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HSCT source</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conditioning regimen</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GvHD prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment arm</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number analysed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age distribution (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Female</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GvHD involvement</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HLA‐haploidentical transplants, haematological malignancies without ongoing or cGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ALL: TBI plus Ara‐C, CY and ATG.</p> <p>AML/MDS: CCNU, Ara‐C, BU, CY and ATG.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MMF, and short term MTX.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18 (15), 18‐40 (39), &gt; 40 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (43), ALL (14), MDS (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (48), CR2 (8), PR (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 18 (13), 18‐40 (43), &gt; 40 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (42), ALL (16), MDS (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (39), CR2 (15), PR (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thalassaemia major</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB or BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CY or fludarabine based</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Class III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Class III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; cGvHD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (3), RIC (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (3 x 10<sup>6</sup> cells/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 45.5 (SD 7.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lymphomas (3), acute leukemias (2), myeloma (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cGvHD: moderate (3), severe (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (1 x 10<sup>6</sup> cells/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 51.1 (SD 10.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lymphomas (6), acute leukemias (2), myeloma (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cGvHD: moderate (4), severe (5)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; aGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (27), RIC (10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX, some additionally received MMF or prednisolone.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 34 (range 20‐63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (14), ALL (2), CML (3), CLL (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR (19), non‐CR (0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 29 (range 19‐60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (10), ALL (4), CML (3), CLL (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR (15), non‐CR (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies in complete remission</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>G‐CSF mobilised BM and PB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BU, CA, CY, ATG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 30 (range 14‐46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (8), AML (13), CML (6), High risk (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (23), CR2 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 31.5 (range 12‐48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (16), AML (7), CML (5), High risk (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (24), CR2 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 13 (range 5‐24) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (8), AML (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 13 (range 5‐24) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (7), AML (4), MDS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB (16), BM (10), PB+BM (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TBI, CY (BU, CY in one patient)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTX</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 38 (range 17‐52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (8), CML (4), ALL (2), MDS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (9), CP (3), first relapse (1), CP2 (1), RAS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 37 (range 16‐61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (7), CML (4), ALL (2), NHL (1), MDS (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CR1 (8), CR2 (1), CP (2), CP2 (2), RAS (1), non‐relapse (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; acute GvHD II‐IV requiring systemic steroid therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB (30), BM (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (15), RIC (8), non‐myeloablative(4), DLI (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CsA (6), tacrolimus (10), tacrolimus plus MMF or MTX (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (8 x 10<sup>6</sup> cells/kg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 49 (range 34‐67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (8), NHL (2), CLL (1), ALL (3), MM (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade II (10), grade III (4), grade IV (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs (2 x 10<sup>6</sup> cells/kg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 53 (range 42‐67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML/MDS (6), NHL (3), CLL (3), ALL (1), MMF (2), MM (0), Hodgkin's (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade II (11), grade III (3), grade IV (2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; newly diagnosed aGvHD grades B‐D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BM/PB/CB/DLI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MTP (or equivalent)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r [192 in total]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r [192 in total]</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B‐D, mostly skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B‐D, mostly skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies; steroid‐refractory aGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PB (197), other (63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MAC (177), other (83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Standard of care"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 42.3 (SD 17.2) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (49), other (124)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B (38), grade C (88), grade D (47).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (ITT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 42.3 (SD 17.2) (all participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AML (23), other (64)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: grade B (23), grade C (50), grade D (14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies (high risk leukaemia)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ALL: CY, etoposide, TBI<br/> AML: BU, CY </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CSA, MTP, ATG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 9.8 (range 3.2‐12.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (3), AML (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd remission (3), MDS (2), Ph (2), monosomy 7 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: none (4), grade I (3), grade II (1).</p> <p>cGvHD: none (7), limited (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 8.5 (range 3.6‐13.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALL (5), AML (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2nd remission (6), 1st remission (2), MDS (2), Ph (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aGvHD: none (4), grade I (5), grade II (2), grade III (1)</p> <p>cGvHD: none (7), limited (4), extensive (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological malignancies, extensive cGvHD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSCs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>extensive cGvHD in skin and/or liver</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>extensive cGvHD in skin and/or liver</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p><b>aGvHD:</b> acute graft‐versus‐host disease; <b>ALL:</b> acute lymphoblastic leukaemia; <b>AML:</b> acute myeloid leukaemia; <b>Ara‐C:</b> arabinosylcytosine; <b>ATG:</b> antithymocyte globulin; <b>BU:</b> busulphan; <b>CA:</b> cytosine arabinoside; <b>CB:</b> cord blood; <b>CCNU:</b> chlorethyl cyclohexyl nitrosourea; <b>cGvHD:</b> chronic graft‐versus‐host disease; <b>CLL:</b> chronic lymphoid leukaemia; <b>CML:</b> chronic myeloid leukaemia; <b>CP:</b> chronic phase; <b>CP2:</b> second chronic phase; <b>CR:</b> complete remission; <b>CR1:</b> complete first remission; <b>CR2:</b> complete second remission; <b>CSA:</b> cyclosporine A; <b>CY:</b> cyclophosphamide; <b>DLI:</b> donor lymphocyte infusion; <b>ITT:</b> intention‐to‐treat; <b>MAC:</b> myeloablative conditioning; <b>MDS:</b> myelodysplastic syndrome; <b>MF:</b> myelofibrosis; <b>MM:</b> multiple myeloma; <b>MMF:</b> mycophenolate mofetil; <b>MSC:</b> mesenchymal stromal cells; <b>MTP:</b> methylprednisolone; <b>MTX:</b> methotrexate; <b>N/A:</b> not applicable;<b>NHL:</b> non‐Hodgkins lymphoma; <b>PB:</b> peripheral blood; <b>Ph:</b> Philadelphia chromosome;<b>PR:</b> partial remission; <b>RAS</b> :refractory anaemia with ringed sideroblasts; <b>RIC:</b> reduced intensity conditioning;<b>TBI:</b> total body irradiation; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009768-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of interventions</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prophylactic or therapeutic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Source of MSCs</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Expansion protocol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose/Schedule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Timing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0001" title="ChiCTR‐IOR‐15006330 . Disease after HLA‐haploidentical stem cell transplantation ‐ A prospective, randomized, parallel‐group study [Efficacy and safety of umbilical cord‐derived mesenchymal stem cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem cell transplantation]. http://www.chictr.org.cn/showproj.aspx?proj=10892 (first received 1 May 2015). GaoL , ZhangY , HuB , LiuJ , KongP , LouS , et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. Journal of Clinical Oncology2016;34(24):2843‐50. ">Gao 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 x 10<sup>7</sup> cells/100mL </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (+4,+5,+6 and +7 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (100 mL normal saline at +4,+5,+6 and +7 months)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45‐1.8 x 10<sup>6</sup> cells/kg given in single intravenous infusion </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (4 hours prior to HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0003" title="EUCTR2008‐004014‐27‐ES . Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft‐versus‐host disease [Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tejido adiposo en pacientes con la enfermedad injerto contra huésped crónica extensa]. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐004014‐27 (first received 10 October 2017). JuradoM , Cardesa GilA , De LaMataC , Ruiz‐GarciaA , Lopez‐FernandezE , EspinosaO , et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GVHD with allogenic mesenchymal stem cells (MSC) from adipose tissue. Cytotherapy2017;9(5 (Suppl.)):S11. JuradoM , De LaMataC , Ruiz‐GarcíaA , López‐FernándezE , EspinosaO , RemigiaMJ , et al. Adipose tissue‐derived mesenchymal stromal cells as part of therapy for chronic graft‐versus‐host disease: A phase I/II study. Cytotherapy2017;19(8):927‐36. NCT01222039 . Multicenter clinical trial for the evaluation of mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease. (CMM/EICH/2008) [Multicenter clinical trial phase I/II randomized, controlled, for the evaluation of safety and feasibility of therapy with two different doses of allogenic mesenchymal stem cells from adipose tissue in patients with chronic graft versus host disease.]. clinicaltrials.gov/show/NCT01222039 (first received 10 October 2017). ">Jurado 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 x 10<sup>6</sup> cells/kg given as a single infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (within first week of cGvHD therapy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 x 10<sup>6</sup> cells/kg given as a single infusion </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0004" title="KuzminaL , ParovichnikovaE , DrokovM , VasilievaV , SorokinaT , PetinatiN , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prospective randomised clinical trial. Bone Marrow Transplantation2015;50(Suppl 1S):S184. KuzminaLA , PetinatiNA , ParovichnikovaEN , LubimovaLS , GribanovaEO , GaponovaTV , et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease ‐ A phase II study. Stem Cells International2012;2012:Article ID 968213. NCT01941394 . Mesenchymal stem cells infusion for aGVHD prophylaxis transplantation [Pilot study for safety and effectiveness assessment of bone marrow mesenchymal stem cell infusion for acute graft‐versus‐host disease prophylaxis and treatment after allogenic bone marrow transplantation]. clinicaltrials.gov/show/NCT01941394 (first received 30 August 2013). PetinatiN , ShipounovaI , BigildeevA , SatsN , DrizeN , KuzminaL , et al. Factors determining the effectiveness of acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation with multipotent mesenchymal stromal cells. Haematologica2015;100(S1):281‐2. PetinatiNA , ShipounovaIN , KuzminaLA , LubimovaLS , ParovichnikovaEN , GribanovaEO , et al. Multipotent mesenchymal stromal cells as graft‐versus‐host disease prophylaxis: A prosective randomised clinical trial. Blood2010;116(21):1256. ShipounovaIN , PetinatiN , BigildeevA , SatsN , DrizeNI , KuzminaLA , et al. Characteristics of mesenchymal multipotent stromal cells determine their effectiveness for acute graft versus host disease prophylaxis after allogeneic bone marrow transplantation. Blood2014;124(21):2484. ShipounovaIN , PetinatiNA , BigildeevAE , ZezinaEA , DrizeNI , KuzminaLA , et al. Analysis of results of acute graft‐versus‐host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry2014;79(12):1363‐70. ">Kuzmina 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelet lysate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜10<sup>6</sup> (range 0.9 ‐ 1.39) cells/kg as single infusion </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (Injected at the time of graft activation (leukocytes &gt;1 x 10<sup>9</sup>/L)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nutrient mixture of F12, 42% MCDB‐201 medium and 58% DMEM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐5 x 10<sup>5</sup> cells/kg </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (within 24 hours of HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 +/‐ 0.4 x 10<sup>6</sup> cells/kg </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (timing n/r)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 3.3 (range 0.3‐15.3) x 10<sup>5</sup> cells/kg given intravenously over 30 minutes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (4 hours prior to HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0008" title="KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Phase II trial of ProchymalTM (ex‐vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft‐vs‐host disease (aGVHD). Blood2006;108(9):3231. KebriaeiP , IsolaL , BahceciE , HollandHK , RowleyS , McGuirkJ , et al. Successful phase II trial using mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft‐vs‐host disease (AGVHD). Biology of Bone Marrow Transplantation2007;13(2 Suppl):111. KebriaeiP , IsolaL , BahceciE , HollandK , RowleyS , McGuirkJ . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation2009;15(7):804‐11. NCT00136903 . Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD [A phase II, randomized study to evaluate the safety and efficacy of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) for the treatment of aGVHD in patients who receive allogeneic hematopoietic stem cell transplantation]. https://clinicaltrials.gov/ct2/show/NCT00136903 (first received 25 August 2005). ">Osiris Protocol 260</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 x 10<sup>6</sup> cells/kg in two infusions given intravenously 3 days apart. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (first infusion within 24‐48 hours of aGvHD diagnosis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 x 10<sup>6</sup> cells/kg in two infusions given intravenously 3 days apart. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0009" title="NCT00562497 . Efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD [A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal™ infusion in combination with corticosteroids for the treatment of newly diagnosed acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00562497 (first received 20 November 2007). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. ">Osiris Protocol 265</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 x 10<sup>6</sup> cells/kg, total 6 infusions over 4 weeks: twice weekly for 2 weeks, then weekly for 2 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (first infusion within 72 hours of aGvHD diagnosis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (excipient, less cells, total 6 infusions over 4 weeks: twice weekly for 2 weeks, then weekly for 2 weeks) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0010" title="Australian Public Assessment Report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. Extract from the clinical evaluation report for Remestemcel‐L, ex vivo adult human mesenchymal stem cells, 2015. Therapeutic Goods Administration, used by permission of the Australian Government [https://www.tga.gov.au/node/537352]. EUCTR2006‐004420‐37‐IT . A phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex‐vivo cultured adult human mesenchymal stem cells) infusion for the treatment of patients who have failed to respond to steroid treatment for acute GVHD. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004420‐37/GB (first received 4 March 2008). MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyA , et al. Prochymal® improves response rates in patients with steroid‐refractory acute graft‐versus‐host disease involving the liver and gut: Results of a randomized, placebo‐controlled, multicentre phase III trial in GvHD. Bone Marrow Transplantation2010;45(Suppl 2S):S17. MartinPJ , UbertiJP , SoifferRJ , KlingemannH , WallerEK , DalyAS , et al. Prochymal improves response rates in patients with steroid‐refractory acute graft versus host disease (SR‐GVHD) involving the liver and gut: Results of a randomized, placebo‐controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplatation2010;16(2 Suppl 2):S169‐170. NCT00366145 . Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease [A phase III, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of Prochymal (ex vivo cultured adult human mesenchymal stem cells) infusion for the treatment of steroid refractory acute GVHD]. https://clinicaltrials.gov/ct2/show/NCT00366145 (first received 17 August 2006). OsirisTherapeutics , Inc . Press Release 8 September 2009: Osiris Therapeutics announces preliminary results for Prochymal phase II GvHD trials. [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekE , et al. Treatment of steroid‐refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo‐controlled study. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S298. SzabolcsP , VisaniG , LocatelliF , KleinerG , TalanoJ , NemecekER , et al. Treatment of steroid‐refractory acute GvHD with mesenchymal stem cells improves outcomes in paediatric patients. Results of the paediatric subset in a phase III randomized, placebo‐controlled study. Bone Marrow Transplantation2010;45(Suppl 2S):S18. ">Osiris Protocol 280</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 x 10<sup>6</sup> cells/kg, given as 8 infusions over 4 weeks, at least 3 days apart </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (timing n/r)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (iv infusions equivalent to the calculated volume of active treatment)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal bovine serum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 7.19 (range 2.44 to 10.12) x 10<sup>6</sup> cells/kg infused over 30 minutes through central venous line </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐transplantation (4 hours prior to HSCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009768-bbs2-0012" title="NCT01526850 . Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host disease (MSCsTcGVHD) [Phase Ⅱ/Ⅲ clinical trial, multicenter, randomized, controlled, for the evaluation of efficacy and safety of therapy with allogenic mesenchymal stem cells in patients with chronic graft versus host disease]. clinicaltrials.gov/show/NCT01526850 (first received 1 February 2012). ZhengW , LuoY , WangS , HanQ , GuoM , ZhouD , et al. MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: A prospective multicentre randomized controlled trial. Bone Marrow Transplantation2015;50(Suppl 1S):S148. ">Zheng 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/r</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4 x 10<sup>7</sup> cells/week, given weekly over four weeks, total 4.8‐16 x 10<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐transplantation (timing n/r)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>AT:</b> adipose tissue; <b>B:M</b> bone marrow; <b>DMEM:</b> Dulbecco's Modified Eagle's medium; <b>UC:</b> umbilical cord; n/r not reported; <b>PL:</b> platelet lysate<b>;BF:</b> fetal bovine serum </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009768-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Engraftment of platelets and neutrophils</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>MSC dose/schedule</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Definition of platelet engraftment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to platelet engraftment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Definition of neutrophil engraftment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to neutrophil engraftment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSCs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No MSCs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSCs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No MSCs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0002" title="GhavamzadehA , AlimoghaddamK , HamidiehAA , KarimiA , BashtarM , ShamshiriAR . Co‐transplantation of HLA‐matched related donors culture‐expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S214. GhavamzadehA , AlimoghaddamK , JahaniM , HamidiehAA , MousaviSA , KhatamiF , et al. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran. Biology of Blood and Marrow Transplantation2010;16(2 Suppl 2):S159. ">Ghavamzadeh 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45‐1.8 x 10<sup>6</sup> cells/kg given in single intravenous infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 20 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 16 days (range n/r)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 15 days (range n/r)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 14 days (range n/r)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 13 days (range n/r)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0005" title="LiuK , ChenY , ZengY , XuL , LiuD , ChenH et , al . Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells and Development2011;20(10):1679‐85. LiuKY , HuangXJ , ChenYH , ChenH , XuLP , ZhaoXH , et al. Cotransplantation of mesenchymal stem cells prompted platelets recovery in HLA‐haploidentical/mismatched blood and marrow transplantation: A randomized phase II study. Blood2008;112(11):3284. LiuKY , ZhaoCH , ChenYH , XuLP , ChenH , LiuDH , et al. A randomized controlled clinical study: coinfusing of mesenchymal stem cells in haploidentical hematopoietic stem‐cell transplantation can facilitate platelet recovery but fail to prevent GVHD. Haematologica2009;94(S2):223‐4. ">Liu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐5 x 10<sup>5</sup> cells/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;20 x 10<sup>9</sup>/L for 7 consecutive days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 19.5 (range 8‐52) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 20 (range 10‐80) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L for 3 consecutive days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 12 (range 10‐21) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 12 (range 10‐23) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0006" title="MareikaI , ShmanT , IsailinaY , MinakovskayaN , AleinikovaO . Influence of mesenchymal stem cells co‐transplantation on post‐transplant period after allogeneic hematopoietic cell transplantation in children with acute leukemia. Bone Marrow Transplantation2016;51(Suppl 1S):S118‐S119. ">Mareika 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 +/‐ 0.4 x 10<sup>6</sup> cells/kg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 18 (range 10‐44) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 23 (range 16‐144) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/r</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 19 (range 12‐20) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 24 (range 16‐45) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0007" title="NingH , YangF , JiangM , HuL , FengK , ZhangJ , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia2008;22(3):593‐9. ">Ning 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 3.3 (range 0.3‐15.3) x 10<sup>5</sup> cells/kg given intravenously over 30 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 x 10<sup>9</sup>/L (first of 3 consecutive days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 30 (range 16‐45) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 27 (15‐64) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L (first of 3 consecutive days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 16 (range 12‐21) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 15 (range 11‐20) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009768-bbs2-0011" title="WuKH , TsaiC , WuHP , SieberM , PengCT , ChaoYH . Human application of ex vivo expanded umbilical cord‐derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplantation2013;22(11):2041‐51. ">Wu 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 7.19 (range 2.44 to 10.12) x 10<sup>6</sup> cells/kg infused over 30 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 20 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 30 (range 20‐45) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 73 (42‐135) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5 x 10<sup>9</sup>/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 12 (range 8‐16) days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 21 (range 17‐43) days</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>n/r not reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Engraftment of platelets and neutrophils</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/full#CD009768-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009768-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">MSCs vs. control/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Prophylactic trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.50, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Therapeutic trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.80, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse of malignant disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term follow‐up (≤ 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.37, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term follow‐up (&gt; 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.73, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 CMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.71, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incidence of aGvHD (prophylactic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.63, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Incidence of cGvHD (prophylactic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Acute GvHD complete response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acute GvHD partial response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Chronic GvHD complete response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Chronic GvHD partial response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">MSCs vs. control/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009768-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">MSCs high dose vs. low dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality (all trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute GvHD complete response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acute GvHD partial response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Chronic GvHD complete response (therapeutic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">MSCs high dose vs. low dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009768-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">MSCs vs. control/placebo: malignant versus non‐malignant disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of aGvHD (prophylactic trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Malignant disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Non‐malignant disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.45, 4.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">MSCs vs. control/placebo: malignant versus non‐malignant disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009768.pub2/references#CD009768-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009768.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009768-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009768-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009768-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009768-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009768-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009768-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009768-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009768\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009768\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009768\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009768\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009768\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009768.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009768.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009768.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009768.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009768.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718692359"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009768.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718692363"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009768.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd68b6ac1f47a',t:'MTc0MDcxODY5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 